Introduction {#s1}
============

In 2006, we published a review with meta-analyses (Lee & Hamling, [@CIT0045]) of the evidence relating environmental tobacco smoking (ETS) exposure to risk of breast cancer in women who had never smoked ("nonsmokers"). Based on results from 22 epidemiological cohort and case-control studies, we noted a weak, but significant, association (random-effects relative risk (RR) = 1.12, 95% confidence interval (95% CI) = 1.02--1.24). However, the estimates were heterogeneous, with risk close to 1.0 for prospective, North American and larger studies, for studies adjusting for many potential confounding variables, and for postmenopausal women. Dose--response analyses were also heterogeneous, and no significant increase was seen for ETS exposure in childhood, in the workplace or specifically from the spouse, though an increase was seen for total exposure. At that time, we noted that increases mainly derived from case-control studies asking detailed histories, where RRs depend heavily on who was classified as having no reported exposure from any of the ETS sources considered, so may be prone to recall bias, and we emphasized the need for results from prospective studies with similar histories. We also noted the implausibility that ETS exposure might cause breast cancer, given the RR for active smoking was so close to 1, and felt that, at that time, one could not confidently conclude that ETS exposure increased risk in nonsmokers.

We also commented on two related major reviews associated with the California EPA Report (California Environmental Protection Agency, [@CIT0005]; Johnson, [@CIT0033]), noting our disagreement with their conclusion that the evidence is consistent with a causal association in younger, primarily premenopausal women. Since then, a number of other expert groups have drawn their own conclusions, which show a considerable degree of disagreement. Thus, while the Canadian Expert Group (Collishaw et al., [@CIT0011]; Johnson et al., [@CIT0036]) essentially agreed with the California Environmental Protection Agency that the data demonstrate a causal relationship in premenopausal women, a more recent report (US Surgeon General, [@CIT0078]) states that "the evidence is suggestive but not sufficient to infer a causal relationship between exposure to secondhand tobacco smoke and breast cancer," while the IARC (International Agency for Research on Cancer, [@CIT0031]; Secretan et al., [@CIT0071]) note that the "evidence for breast cancer remains inconclusive" and do not include breast cancer in the list of cancers for which "sufficient evidence" has been demonstrated of a causal relationship with ETS. The review by the Oxford Group (Pirie et al., [@CIT0059]) is even more dismissive of a causal relationship, noting (consistently with a more recent review -- Yang et al., [@CIT0088]) that the "aggregate results from studies with prospectively reported information show that the incidence of breast cancer is similar in women who did and did not report passive smoke exposure to tobacco smoke whether as a child or as an adult" and that "the aggregate results from the retrospective studies may have been distorted by some women becoming more likely to report past exposures because they knew that they had breast cancer."

Since our earlier review (Lee & Hamling, [@CIT0045]), studies providing data have proliferated, and none of the later reviews mentioned above cite publications later than 2011. It seems timely, therefore, to carry out an updated review incorporating more recent publications. The methodology used is essentially as described earlier.

As before, and as is usual in studies of ETS and health for reasons discussed elsewhere (Lee, [@CIT0041]), we restrict attention to studies where the relationship between ETS exposure and breast cancer mortality or incidence has been studied in nonsmokers. This requirement means that some publications which might at first seem relevant have not been considered. These include a number of studies in China considered in two recent reviews (Chen et al., [@CIT0006],[@CIT0007]) as well as various other studies (Bradbury et al., [@CIT0004]; Gao et al., [@CIT0020]; Hirose et al., [@CIT0025]; Hosseinzadeh et al., [@CIT0026]; Hsieh et al., [@CIT0027]; Hu et al., [@CIT0028]; Kruk, [@CIT0038]; Marcus et al., [@CIT0051]; Marufu et al., [@CIT0052]; Qi et al., [@CIT0060]; Sanderson et al., [@CIT0069]; Wang et al., [@CIT0081],[@CIT0080]; Weiss et al., [@CIT0083]; Zhao et al., [@CIT0090]).

Methods {#s2}
=======

The methods used, essentially as described earlier (Lee & Hamling, [@CIT0045]), are summarized below. In June 2015, publications describing results of studies relating breast cancer risk in lifelong nonsmoking women to ETS exposure were sought from MEDLINE searches, in-house files and reference lists of papers retrieved. The search terms "(passive smoking OR environmental tobacco smoke OR involuntary smoking) AND breast cancer" were used. Studies not in humans, of ecological design, or not providing results for nonsmokers were rejected. Studies included in our previous review (Lee & Hamling, [@CIT0045]) were included.

From the selected studies, details were extracted of study location and design and of potential confounding variables considered. Where available, RR estimates and their 95% CI were extracted for various sources of ETS exposure: at home, at work, in adulthood, in childhood and throughout life. As before, we use the term "relative risk" to include odds ratios from case-control studies, as well as hazard ratios from prospective studies. For each exposure, the RR adjusted for the most potential confounding variables was selected for analysis. Overall RRs were estimated from RRs given by grouped level of exposure (e.g. 1--2, 3--5, 6 + h/day), genetic type, or other subgroup as described earlier (Lee & Hamling, [@CIT0045]). For a given source of exposure (e.g. at work), RRs generally compared women who were exposed or unexposed to the specific source, exceptions, where the reference group included women with a low exposure, being noted in the tables. RRs were also extracted by subgroup, where available. We also determined whether studies provided dose--response data, and if so, whether there was significant (*p* \< 0.05) evidence of a trend within the exposed groups.

Fixed-effect and random-effects meta-analyses were conducted (Fleiss & Gross, [@CIT0017]), with tests of publication bias also carried out (Egger et al., [@CIT0016]). We also tested whether the results from a specific study could be regarded as an outlier, by treating the drop in deviance (chi-squared) from excluding the result divided by the mean deviance for the remaining studies as an *F* statistic, and rerunning the meta-analysis excluding the study if the associated probability was \<0.01.

These methods of analysis were applied separately to data for six ETS exposure indices; from the spouse, at home, at the workplace, overall adulthood, in childhood and total during lifetime. They were also applied in a "principal" meta-analysis in which one result was selected from each study, based first on source of exposure (choosing spouse as the highest preference, then partner, cohabitant, exposure at home or work) and second on time of exposure (for spouse or partner preferring ever to current, and, for other types of exposures, preferring adulthood to ever in life). This was intended to produce an index most closely equivalent to "spouse ever smoked". For these seven indices, additional analyses were also conducted by study type separated into two groups (prospective or nested case-control studies, and other case-control studies) reflecting whether ETS exposure was or was not determined before disease onset. For the principal meta-analysis, further subgroup analyses were conducted by region (North America, Asia, Europe), study size (\>500, \<500 cases), confounders adjusted for (age and 9+ others, \<9 or 9+ but not including age), detailed exposure assessment (yes, no), and study type × detailed assessment. A study was regarded as having made a detailed assessment if it separately asked questions about childhood exposure, at home exposure in adulthood (spousal or any cohabitant) and other sources of exposure in adulthood (e.g. workplace). Subgroup analyses were also conducted excluding studies published only as abstracts, by length of follow-up for prospective studies (≤10, 11+ years) and by type of control for case-control studies (population, other).

For each study included in the principal meta-analysis which provided results by level of adjustment for potential confounding variables, the ratio was calculated of the most-adjusted RR estimate (as used in the principal meta-analysis) to the corresponding least-adjusted RR estimate. The overall effect of confounding, in these studies was then estimated from the geometric mean of these ratios.

Unless otherwise indicated, the word "significant" is taken to indicate significance at *p* \< 0.05.

Results {#s3}
=======

The studies {#s3A}
-----------

Some details of the 47 studies are summarized in [Table 1](#t0001){ref-type="table"}. Two studies were published in the 1980s, four in the 1990s, 16 from 2000 to 2005, 14 from 2006 to 2010, and 11 from 2011 to June 2015, reflecting increasing interest in the possibility that ETS might cause breast cancer. Four studies (Chilian-Herrera et al., [@CIT0008]; Rookus et al., [@CIT0067]; Woo et al., [@CIT0086]; Zhu et al., [@CIT0091]) were published only as abstracts. Young et al. ([@CIT0089]) reports a combination of two studies, one reported extensively by Anderson et al. ([@CIT0002]). To avoid overlap no result from Young et al. ([@CIT0089]) is included in the principal meta-analysis.

###### Studies providing data on ETS and breast cancer.

  Study[^a^](#TF1){ref-type="table-fn"}                                                         Year[^b^](#TF2){ref-type="table-fn"}   Location                                          Design[^c^](#TF3){ref-type="table-fn"}   ETS sources[^d^](#TF4){ref-type="table-fn"}   Subgroup analysis[^e^](#TF5){ref-type="table-fn"}
  --------------------------------------------------------------------------------------------- -------------------------------------- ------------------------------------------------- ---------------------------------------- --------------------------------------------- ---------------------------------------------------
  Sandler et al., [@CIT0070]; Wells, [@CIT0084]; Wells, [@CIT0116]                              1985                                   USA, North Carolina                               CC-F                                     Sp, Ch                                        Yes
  Hirayama, [@CIT0024]; Wells, [@CIT0084]; Wells, [@CIT0116]                                    1987                                   Japan, six prefectures                            P(16)                                    Sp                                            Yes
  Smith et al., [@CIT0074]                                                                      1994                                   UK, 11 regions                                    CC-P                                     Sp, Oc, Wk, Aa, Ch, To,\*                     --
  Morabia et al., [@CIT0056]; Morabia et al., [@CIT0113]; Morabia et al., [@CIT0114]            1996                                   Switzerland, Geneva                               CC-P                                     Sp, To[^f^](#TF6){ref-type="table-fn"},\*     Yes
  Jee et al., [@CIT0032]                                                                        1999                                   Korea, nationwide                                 P(6)                                     Sp                                            --
  Lash & Aschengrau, [@CIT0039]                                                                 1999                                   USA, Massachusetts                                CC-P                                     Co, Ch                                        --
  Delfino et al., [@CIT0014]                                                                    2000                                   USA, California                                   CC-B                                     Co                                            Yes
  Johnson et al., [@CIT0035]                                                                    2000                                   Canada, eight provinces                           CC-P                                     Aa, Ch, To,\*                                 Yes
  Liu et al., [@CIT0048]                                                                        2000                                   China, Chongqing                                  CC-H                                     Co, Wk, Ch,\*                                 --
  Rookus et al., [@CIT0067]                                                                     2000                                   Netherlands, Amsterdam                            CC-P                                     To,\*                                         Yes
  Wartenberg et al., [@CIT0082]                                                                 2000                                   USA, 50 states[^g^](#TF7){ref-type="table-fn"}    P(12)                                    Sp, Co, Wk, Aa,\*                             Yes
  Woo et al., [@CIT0086]                                                                        2000                                   USA, Maryland                                     NCC                                      Co                                            Yes
  Nishino et al., [@CIT0058]                                                                    2001                                   Japan, Miyagi                                     P(9)                                     Sp, Oc                                        --
  Chang-Claude et al., [@CIT0037]; Kropp & Chang-Claude, [@CIT0037]; Lilla et al., [@CIT0107]   2002                                   Germany, two regions                              CC-P                                     Aa, Ch, To,\*                                 Yes
  Lash & Aschengrau, [@CIT0040]                                                                 2002                                   USA, Massachusetts                                CC-P                                     Co, Ch                                        --
  Alberg et al., [@CIT0001]                                                                     2004                                   USA, Washington County                            NCC                                      Sp                                            Yes
  Gammon et al., [@CIT0018]; Gaudet et al., [@CIT0101]; Mordukhovich et al., [@CIT0115]         2004                                   USA, New York                                     CC-P                                     Co                                            Yes
  Shrubsole et al., [@CIT0072]                                                                  2004                                   China, Shanghai                                   CC-P                                     Sp, Wk, Aa                                    Yes
  Bonner et al., [@CIT0003]                                                                     2005                                   USA, New York state                               CC-P                                     Co, Wk, Ch,\*                                 Yes
  Gram et al., [@CIT0022]                                                                       2005                                   Norway and Sweden                                 P(10)                                    Co                                            --
  Hanaoka et al., [@CIT0023]                                                                    2005                                   Japan, 14 districts                               P(10)                                    Co, Wk, To,\*                                 Yes
  Metsola et al., [@CIT0111]; Sillanpää et al., [@CIT0073]                                      2005                                   Finland, Kuopio                                   CC-P                                     To,\*                                         Yes
  Lissowska et al., [@CIT0109], [@CIT0108]                                                      2006                                   Poland, Warsaw and Łódź                           CC-P                                     Co, Wk, To,\*                                 Yes
  Furberg et al., [@CIT0106]; Mechanic et al., [@CIT0053]; Millikan et al., [@CIT0112]          2006                                   USA, North Carolina                               CC-P                                     Co                                            Yes
  Zhu et al., [@CIT0091]                                                                        2006                                   China, Shanghai                                   P(7)                                     To                                            Yes
  Roddam et al., [@CIT0065]                                                                     2007                                   UK, three regions                                 CC-G                                     Sp                                            Yes
  Lin et al., [@CIT0047]                                                                        2008                                   Japan, nationwide                                 P(13)                                    Co, Ch,\*                                     --
  Pirie et al., [@CIT0059]                                                                      2008                                   UK, nationwide                                    P(3.5)                                   Sp, Ch, To                                    Yes
  Rollison et al., [@CIT0066]                                                                   2008                                   USA, Delaware                                     CC-P                                     Co, Wk, Ch, To,\*                             --
  Slattery et al., [@CIT0110]                                                                   2008                                   USA, four states                                  CC-P                                     Ch, To,\*                                     Yes
  Ahern et al., [@CIT0102]                                                                      2009                                   USA, Massachusetts                                CC-P                                     Aa, Ch, To,\*                                 --
  Reynolds et al., [@CIT0062; @CIT0064; @CIT0063]                                               2009                                   USA, California                                   P(10)                                    Co, Wk, Aa, Ch, To,\*                         Yes
  Young et al., [@CIT0089]                                                                      2009                                   Canada, Ontario[^h^](#TF8){ref-type="table-fn"}   CC-P                                     To,\*                                         --
  Chilian-Herrera et al., [@CIT0008]                                                            2010                                   Mexico, US border states                          CC-P                                     To,\*                                         Yes
  Conlon et al., [@CIT0012]                                                                     2010                                   Canada, Ontario                                   CC-P                                     To,\*                                         Yes
  De Silva et al., [@CIT0013]                                                                   2010                                   Sri Lanka, Western province                       CC-P                                     To[^i^](#TF9){ref-type="table-fn"}            --
  Luo et al., [@CIT0049]                                                                        2011                                   USA, nationwide                                   P(10)                                    Co, Wk, Aa, Ch, To,\*                         Yes
  Egan et al., [@CIT0105]; Xue et al., [@CIT0087]                                               2011                                   USA, 11 states                                    P(24)                                    Co, Wk, Aa, Ch,\*                             Yes
  Anderson et al., [@CIT0002]                                                                   2012                                   Canada, Ontario                                   CC-P                                     Co, Wk, Aa, Ch,\*                             Yes
  Ilic et al., [@CIT0029]                                                                       2013                                   Serbia, Kragujevac                                CC-H                                     Aa                                            --
  Rosenberg et al., [@CIT0068]                                                                  2013                                   USA, Nationwide                                   P(14)                                    To,\*                                         Yes
  Tang et al., [@CIT0075]                                                                       2013                                   China, Guangzhou                                  CC-H                                     Co, Wk, Aa                                    Yes
  Chuang et al., [@CIT0009]; Dossus et al., [@CIT0015]                                          2014                                   Europe, 10 countries                              P(18)                                    Co, Wk, Aa, Ch, To,\*                         --
  Nishino et al., [@CIT0057]                                                                    2014                                   Japan, Miyagi Prefecture                          CC-H                                     Sp                                            Yes
  Tong et al., [@CIT0076]                                                                       2014                                   China, Liaoning Province                          CC-H                                     Sp[^j^](#TF10){ref-type="table-fn"}           Yes
  Li et al., [@CIT0046]                                                                         2015                                   China, Guangdong Province                         CC-H                                     Co, Wk, Aa,\*                                 Yes
  Wada et al., [@CIT0079]                                                                       2015                                   Japan, Takayama City                              P(16)                                    Sp                                            Yes

For each study the main publication is shown first in the list of sources. Studies are in chronological order of the main publication.

Year of main publication.

Design *P*(*n*) prospective study with *n* years of follow-up. CC: case-control study; controls indicated by: -B: benign breast disease; -F: friends of cases; -G: same general practitioner; -H: hospital patients without cancer; -P: population sample; NCC: case-control study nested within a prospective study.

ETS sources for which results are available: Sp: spouse (or partner); Aa: any adult exposure; Co: cohabitant; Ch: childhood exposure; Oc: other cohabitants (not spouse); To: total lifetime exposure (childhood and adulthood); Wk: workplace. An asterisk (\*) indicates that the study reported asking separately about childhood, adult at home, and other adult exposure, so is classified as collecting detailed exposure data.

Subgroup analysis. Yes: results are reported that relate ETS to breast cancer separately by levels of exposure for at least one exposure index. See [Table 10](#t0010){ref-type="table"} and [Supplementary item 2](http://dx.doi.org/10.1080/08958378.2016.1210701) for details.

Questions were asked about exposures from age 10.

Also District of Columbia and Puerto Rico.

Combines data from study by Anderson et al. ([@CIT0002]) plus another study although different exposure considered. Not included in principal meta-analysis.

Active smoking appears to have been ignored in this study, although another source is quoted stating that only 0.6% of Sri Lankan women smoke.

Women who lived with two or more smokers were excluded from the study.

The 47 studies included all the 22 that had been considered in our earlier review -- those 15 with a main publication year up to 2002, four published in 2004 or 2005 (Gammon et al., [@CIT0018]; Gram et al., [@CIT0022]; Hanaoka et al., [@CIT0023]; Shrubsole et al., [@CIT0072]) and three were results from a later publication that has since become available (Mechanic et al., [@CIT0053]; Reynolds et al., [@CIT0062]; Xue et al., [@CIT0087]).

Twenty-two of the 47 studies were conducted in North America, 14 in Asia and 11 in Europe.

Thirty of the studies were of case-control design, six with upper age limits: of 36 years (Smith et al., [@CIT0074]), 45 years (Roddam et al., [@CIT0065]), 50 years (Gram et al., [@CIT0022]; Kropp & Chang-Claude, [@CIT0037]), 54 years (Rookus et al., [@CIT0067]) and 55 years (Liu et al., [@CIT0048]). The remaining case-control studies included older women.

Fifteen studies were prospective, with follow-up ranging from 3.5 to 24 years. Most concerned breast cancer onset, but Hirayama ([@CIT0024]) and Wartenberg et al. ([@CIT0082]) were of mortality, based on death certificates. Two further studies (Alberg et al., [@CIT0001]; Woo et al., [@CIT0086]) were case-control studies nested within prospective studies.

The case-control studies mainly used population controls. However, Sandler et al. ([@CIT0070]) used friends of cases as controls, possibly unrepresentative of the population, since friends, compared to random members of the population, tend to be more similar in respect of various factors, such as education and alcohol consumption. Also seven case-control studies used hospital-based controls: benign breast disease patients (Delfino et al., [@CIT0014]), patients with "other diseases" (Ilic et al., [@CIT0029]) and patients without cancer (Li et al., [@CIT0046]; Liu et al., [@CIT0048]; Nishino et al., [@CIT0057]; Tang et al., [@CIT0075]; Tong et al., [@CIT0076]). Most case-control studies obtained the information from the subject, but Lash & Aschengrau ([@CIT0039],[@CIT0040]) used proxy interviews for deceased cases and their matched controls.

Results for various ETS exposure indices were reported. Seven studies (Alberg et al., [@CIT0001]; Hirayama, [@CIT0024]; Jee et al., [@CIT0032]; Nishino et al., [@CIT0057]; Roddam et al., [@CIT0065]; Tong et al., [@CIT0076]; Wada et al., [@CIT0079]) only recorded exposure from the spouse or partner, while 10 further studies (Delfino et al., [@CIT0014]; Gammon et al., [@CIT0018]; Gram et al., [@CIT0022]; Lash & Aschengrau, [@CIT0039],[@CIT0040]; Lin et al., [@CIT0047]; Mechanic et al., [@CIT0053]; Pirie et al., [@CIT0059]; Sandler et al., [@CIT0070]; Woo et al., [@CIT0086]) only considered at-home exposure. The other studies collected more extensive information.

Twenty-five of the studies, indicated by an asterisk in the ETS sources column in [Table 1](#t0001){ref-type="table"}, collected data on ETS exposure in childhood, in adulthood at home and in adulthood at work (or outside the home), though a number of these did not report results for a combined index based on all their exposure sources. These 25 studies have been classified, for the purposes of subgroup analysis, as providing "detailed" ETS data. Other studies either clearly did not collect detailed data, as defined, or provided insufficient information to confirm that they did.

While most studies presented results comparing women exposed or unexposed to the source of interest, some required a minimum level of exposure to count as exposed. Thus, Morabia et al. ([@CIT0056]) and Kropp and Chang-Claude ([@CIT0037]) required at least an hour a day exposure for a year, Johnson et al. ([@CIT0035]) required women to be in the presence, specifically, of regular smokers, and Rookus et al. ([@CIT0067]) defined exposure as "exposed daily to the smoke of home-mates or colleagues during at least 20 years or if someone smoked daily in their bedroom during more than one year." Also, Chilian-Herrera et al. ([@CIT0008]) presented results for "t3 versus t1" with no explanation beyond that the reference group consisted of never active smokers with no history of passive smoking exposure, Rosenberg et al. ([@CIT0068]) required exposure for at least an hour a day for at least 12 consecutive months and restricted attention to exposure up to age 30, and Tong et al. (2014) required exposure for at least a year and excluded women living with more than one smoker.

[Supplementary item 1](http://dx.doi.org/10.1080/08958378.2016.1210701) lists the potential confounding variables adjusted for. The studies published only as abstracts (Chilian-Herrera et al., [@CIT0008]; Rookus et al., [@CIT0067]; Woo et al., [@CIT0086]; Zhu et al., [@CIT0091]) did not clarify which variables had been adjusted for, while the presentation in Conlon et al. ([@CIT0012]) allowed only unadjusted results to be used. Of the others, all adjusted for age except for Hirayama ([@CIT0024]) (which adjusted for age of the husband), De Silva et al. ([@CIT0013]) and Ilic et al. ([@CIT0029]). Sandler et al. ([@CIT0070]), Hirayama ([@CIT0024]) and Young et al. ([@CIT0089]) adjusted for no other variables, but the other studies adjusted for between two and 16 variables. Other variables adjusted for in at least 10 studies included age at menarche, age at pregnancy (or birth), parity (or numbers of births), family history of breast cancer, personal history of benign breast disease, alcohol consumption, menopausal status (or age at menopause), body mass index (or other similar indices of obesity), physical activity, education (or socio-economic status) and hormone use. These are all well-established breast cancer risk factors (Gammon et al., [@CIT0019]; Madigan et al., [@CIT0050]). Other less commonly considered variables included aspects of diet and breastfeeding.

RR estimates and meta-analyses for different sources of ETS exposure {#s3B}
--------------------------------------------------------------------

[Tables 2--7](#t0002 t0003 t0004 t0005 t0006 t0007){ref-type="table"} give RRs for six different sources of ETS exposure and [Table 8](#t0008){ref-type="table"} gives results of meta-analyses based on these data.

###### RR of breast cancer in lifelong nonsmoking women according to ETS exposure from the spouse.

  Study[^a^](#TF11){ref-type="table-fn"}                                                                                                   Study location   Study type[^b^](#TF12){ref-type="table-fn"}   Source of exposure (timing)[^c^](#TF13){ref-type="table-fn"}   Number of breast cancers[^d^](#TF14){ref-type="table-fn"}   RR (95% CI)                       Dose response[^e^](#TF15){ref-type="table-fn"}   Notes[^f^](#TF16){ref-type="table-fn"}
  ---------------------------------------------------------------------------------------------------------------------------------------- ---------------- --------------------------------------------- -------------------------------------------------------------- ----------------------------------------------------------- --------------------------------- ------------------------------------------------ ----------------------------------------
  Wells, [@CIT0116] reporting the  Sandler et al., [@CIT0070] study[^g^](#TF17){ref-type="table-fn"}^,^[^h^](#TF18){ref-type="table-fn"}   USA              CC                                            Spouse (ever)                                                  32                                                          1.62 (0.76--3.44)                 --                                               am
  Wells, [@CIT0116] reporting the  Hirayama, [@CIT0024] study[^h^](#TF18){ref-type="table-fn"}                                             Japan            P                                             Spouse (ever)                                                  115                                                         1.32 (0.83--2.09)                 No                                               c(1)m
  Smith et al., [@CIT0074]                                                                                                                 UK               CC                                            Spouse/partner (adulthood)                                     94                                                          1.58 (0.81--3.10)                 --                                               ac(9)m
  Morabia et al., [@CIT0056]                                                                                                               Switzerland      CC                                            Spouse (ever)[^i^](#TF19){ref-type="table-fn"}                 90                                                          3.1 (1.6--6.1)                    No                                               ac(9)m
  Jee et al., [@CIT0032]                                                                                                                   Korea            P                                             Spouse (ever)                                                  138                                                         1.27 (0.91--1.77)                 --                                               ac(5)em
  Wartenberg et al., [@CIT0082][^h^](#TF18){ref-type="table-fn"}                                                                           USA              P                                             Spouse (ever)Spouse (current)                                  669439                                                      1.00 (0.84--1.19)1.0 (0.8--1.2)   No--                                             ac(16)emac(16)
                                                                                                                                                                                                          Spouse (former)                                                503                                                         1.0 (0.8--1.2)                    --                                               ac(16)
  Nishino et al., [@CIT0058]                                                                                                               Japan            P                                             Spouse (current)                                               67                                                          0.58 (0.32--1.10)                 --                                               ac(8)m
  Alberg et al., [@CIT0001][^g^](#TF17){ref-type="table-fn"}^,h^                                                                           USA              NCC                                           Spouse (ever)                                                  62                                                          1.20 (0.59--2.40)                 --                                               ac(4)m
  Shrubsole et al., [@CIT0072][^g^](#TF17){ref-type="table-fn"}                                                                            China            CC                                            Spouse (ever)                                                  813                                                         1.0 (0.8--1.2)                    No                                               ac(10)m
  Roddam et al., [@CIT0065][^g^](#TF17){ref-type="table-fn"}^,h^                                                                           UK               CC                                            Spouse/partner (ever)                                          297                                                         0.89 (0.64--1.25)                 No                                               ac(9)m
  Pirie et al., [@CIT0059]                                                                                                                 UK               P                                             Spouse/partner (current)                                       1915                                                        1.02 (0.89--1.16)                 --                                               ac(10)m
  Nishino et al., [@CIT0057][^g^](#TF17){ref-type="table-fn"}^,h^                                                                          Japan            CC                                            Spouse (ever)                                                  773                                                         1.09 (0.91--1.31)                 --                                               ac(15)em
  Tong et al., [@CIT0076][^h^](#TF18){ref-type="table-fn"}                                                                                 China            CC                                            Spouse (ever)                                                  312                                                         1.46 (1.05--2.03)                 d1                                               ac(6)m
  Wada et al., [@CIT0079][^g^](#TF17){ref-type="table-fn"}^,h^                                                                             Japan            P                                             Spouse (ever)                                                  107                                                         1.58 (0.89--2.83)                 No                                               ac(9)em

Studies are in chronological order of the main publication.

Study type: P: prospective; CC: case-control; NCC: nested case control.

Reference group is all lifelong nonsmokers unexposed to the given source, except where indicated by a reference to other notes.

Number of breast cancers in lifelong nonsmokers in the analysis reported.

Dose response: "--" indicates dose response not studied, "No" indicates dose--response studied but no significant trend seen within the exposed groups, otherwise: d1: RRs are 1.21, 1.99 for 1--5, \>5 cigarettes smoked per day by the spouse (trend *p* \< 0.05). No significant trend for years smoking by the spouse, or for pack-years of smoking by the spouse.

Notes: a: adjusted for age of subject; c: adjusted for other confounding variables (see [Supplementary item 1](http://dx.doi.org/10.1080/08958378.2016.1210701)) -- number of variables adjusted for is shown in brackets; e: estimated from data reported; m: included in principal meta-analyses (see [Table 9](#t0009){ref-type="table"}).

See [Table 10](#t0010){ref-type="table"} for pre/post menopausal results for this analysis.

See [Supplementary item 2](http://dx.doi.org/10.1080/08958378.2016.1210701) for other subgroup results for this analysis.

Reference group is less than 1 h/day ETS exposure from any source for 12 consecutive months during life.

###### RR of breast cancer in lifelong nonsmoking women according to ETS exposure at home, other than spouse-only exposure.

  Study[^a^](#TF20){ref-type="table-fn"}                                                             Study location      Study type[^b^](#TF21){ref-type="table-fn"}   Source of exposure (timing)[^c^](#TF22){ref-type="table-fn"}               Number of breast cancers[^d^](#TF23){ref-type="table-fn"}   RR (95% CI)                          Dose response[^e^](#TF24){ref-type="table-fn"}   Notes[^f^](#TF25){ref-type="table-fn"}
  -------------------------------------------------------------------------------------------------- ------------------- --------------------------------------------- -------------------------------------------------------------------------- ----------------------------------------------------------- ------------------------------------ ------------------------------------------------ ----------------------------------------
  \*Smith et al., [@CIT0074]                                                                         UK                  CC                                            Cohabitant other than the spouse (adulthood)                               94                                                          1.36 (0.67--2.77)                    No                                               ac(9)e
  Lash & Aschengrau, [@CIT0039][^g^](#TF26){ref-type="table-fn"}                                     USA                 CC                                            Cohabitant (ever)                                                          120                                                         2.0 (1.1--3.7)                       No                                               ac(7)m
  Delfino et al., [@CIT0014][^g^](#TF26){ref-type="table-fn"}^,^[^h^](#TF27){ref-type="table-fn"}    USA                 CC                                            Cohabitant (ever)[^i^](#TF28){ref-type="table-fn"}                         64                                                          1.50 (0.79--2.87)                    --                                               ac(2)m
  Liu et al., [@CIT0048]                                                                             China               CC                                            Cohabitant (adulthood)                                                     186                                                         1.49 (0.96--2.30)                    d1                                               ac(2)em
  \*Wartenberg et al., [@CIT0082][^g^](#TF26){ref-type="table-fn"}                                   USA                 P                                             Cohabitant (current)                                                       669                                                         1.1 (0.9--1.3)                       --                                               ac(16)
  Woo et al., [@CIT0086]                                                                             USA                 NCC                                           Cohabitant (current)                                                       \(706\)                                                     1.03 (0.81--1.31)                    --                                               c(?)em
  \*Nishino et al., [@CIT0058]                                                                       Japan               P                                             Cohabitant other than the spouse (current)                                 67                                                          0.81 (0.44--1.50)                    --                                               ac(8)
  Lash & Aschengrau, [@CIT0040][^h^](#TF27){ref-type="table-fn"}                                     USA                 CC                                            Cohabitant (ever)                                                          305                                                         0.85 (0.63--1.1)                     No                                               ac(9)m
  Gammon et al., [@CIT0018][^g^](#TF26){ref-type="table-fn"}^,^[^h^](#TF27){ref-type="table-fn"}     USA                 CC                                            Cohabitant (ever)[^j^](#TF29){ref-type="table-fn"}                         598                                                         1.04 (0.81--1.35)                    No                                               ac(7)m
  Bonner et al., [@CIT0003][^g^](#TF26){ref-type="table-fn"}                                         USA                 CC                                            Cohabitant (ever)                                                          525                                                         1.18 (0.86--1.63)                    No                                               ac(11)em
  Gram et al., [@CIT0022]                                                                            Norway and Sweden   P                                             Cohabitant (ever)                                                          \(1130\)                                                    1.21 (0.98--1.50)                    --                                               ac(8)m
  Hanaoka et al., [@CIT0023][^g^](#TF26){ref-type="table-fn"}                                        Japan               P                                             Cohabitant (ever)[^k^](#TF30){ref-type="table-fn"}                         154                                                         1.0 (0.7--1.4)                       --                                               ac(11)m
  Lissowska et al., [@CIT0109]                                                                       Poland              CC                                            Cohabitant (ever)                                                          1034                                                        0.92 (0.74--1.14)                    --                                               ac(12)em
  Mechanic et al., [@CIT0053][^g^](#TF26){ref-type="table-fn"}^,^[^h^](#TF27){ref-type="table-fn"}   USA                 CC                                            Cohabitant (adulthood)                                                     1211                                                        1.10 (0.93--1.31)                    --                                               ac(6)em
  Lin et al., [@CIT0047]                                                                             Japan               P                                             Cohabitant (past)                                                          131                                                         0.68 (0.47--0.97)                    No                                               ac(10)em
  Rollison et al., [@CIT0066]                                                                        USA                 CC                                            Cohabitant (adulthood)                                                     124                                                         0.98 (0.58--1.64)                    --                                               ac(8)m
  Reynolds et al., [@CIT0064][^g^](#TF26){ref-type="table-fn"}                                       USA                 P                                             Cohabitant (adulthood)[^l^](#TF31){ref-type="table-fn"}Cohabitant (ever)   11501164                                                    0.97 (0.87--1.10)0.94 (0.82--1.07)   ----                                             ac(11)emac(11)
  Luo et al., [@CIT0049]                                                                             USA                 P                                             Cohabitant (adulthood)                                                     1660                                                        1.00 (0.91--1.11)                    --                                               ac(10)em
  Xue et al., [@CIT0087]                                                                             USA                 P                                             Cohabitant (adulthood)                                                     2874                                                        0.99 (0.92--1.07)                    No                                               ac(15)em
  Anderson et al., [@CIT0002][^g^](#TF26){ref-type="table-fn"}                                       Canada              CC                                            Cohabitant (adulthood)                                                     918                                                         1.08 (0.89--1.31)                    No                                               ac(1)em
  Tang et al., [@CIT0075]                                                                            China               CC                                            Cohabitant (adulthood)                                                     765                                                         1.55 (1.23--1.96)                    --                                               ac(9)m
  Dossus et al., [@CIT0015]                                                                          Europe              P                                             Cohabitant (current)                                                       3286                                                        1.03 (0.94--1.13)                    --                                               ac(11)em
  Li et al., [@CIT0046][^g^](#TF26){ref-type="table-fn"}^,^[^h^](#TF27){ref-type="table-fn"}         China               CC                                            Cohabitant (adulthood)                                                     877                                                         1.40 (1.15--1.71)                    d2                                               ac(10)em

Studies are in chronological order of the main publication. Studies marked \* also provide estimates for ETS exposure from the spouse: see [Table 2](#t0002){ref-type="table"}.

Study type: P: prospective; CC: case-control; NCC: nested case control.

Reference group is all lifelong nonsmokers unexposed to the given source, except where indicated by a reference to other notes.

Number of breast cancers in lifelong nonsmokers in the analysis reported; where this is not known total number of cases in ever smokers is given in brackets.

Dose response: "--" indicates dose response not studied, "No" indicates dose--response studied but no significant trend seen within the exposed groups, otherwise: d1: RRs are 0.47, 1.64, 2.14, 3.09 for light, medium, heavy, very heavy exposure from cohabitants (trend *p* \< 0.01). No significant trend for number of smokers at home; d2: RRs are 1.06, 1.18, 1.66 for 1--15, 16--25, 26+ smoker-years exposure at home (trend *p* \< 0.05). No significant trend for cigarettes per day smoked by the family at home, or for pack-years exposure at home.

Notes: a: adjusted for age of subject; c: adjusted for other confounding variables (see [Supplementary item 1](http://dx.doi.org/10.1080/08958378.2016.1210701)) -- number of variables adjusted for is shown in brackets with "?" representing an unknown number of adjustment variables; e: estimated from data reported; m: included in principal meta-analyses (see [Table 9](#t0009){ref-type="table"}).

See [Table 10](#t0010){ref-type="table"} for pre/post menopausal results for this analysis.

See [Supplementary item 2](http://dx.doi.org/10.1080/08958378.2016.1210701) for other subgroup results for this analysis.

Cohabitant(s) smoked in their home usually or some of the time.

Results are also reported for spouse (ever) but have not been included in [Table 2](#t0002){ref-type="table"} as they appear to be based on ever smokers as well as never smokers.

Reference group is never exposed at home during life and not exposed daily outside the home at baseline.

Based on 6 years of follow-up only.

###### RR of breast cancer in lifelong nonsmoking women according to ETS exposure in the workplace.

  Study[^a^](#TF32){ref-type="table-fn"}                                                             Study location   Study type[^b^](#TF33){ref-type="table-fn"}   Source of exposure (timing)[^c^](#TF34){ref-type="table-fn"}                  Number of breast cancers[^d^](#TF35){ref-type="table-fn"}   RR (95% CI)         Dose response[^e^](#TF36){ref-type="table-fn"}   Notes[^f^](#TF37){ref-type="table-fn"}
  -------------------------------------------------------------------------------------------------- ---------------- --------------------------------------------- ----------------------------------------------------------------------------- ----------------------------------------------------------- ------------------- ------------------------------------------------ ----------------------------------------
  Smith et al., [@CIT0074]                                                                           UK               CC                                            Workplace (NOS)                                                               94                                                          1.49 (0.76--2.92)   No                                               ac(9)e
  Liu et al., [@CIT0048]                                                                             China            CC                                            Workplace (NOS)                                                               186                                                         1.54 (1.02--2.32)   No                                               eu
  Wartenberg et al., [@CIT0082]                                                                      USA              P                                             Workplace (current)                                                           669                                                         0.8 (0.6--1.0)      --                                               ac(16)
  Shrubsole et al., [@CIT0072][^h^](#TF39){ref-type="table-fn"}                                      China            CC                                            Workplace (last 5 years)[^i^](#TF40){ref-type="table-fn"}                     864                                                         1.1 (0.9--1.4)      d1                                               ac(10)
  Bonner et al., [@CIT0003][^g^](#TF38){ref-type="table-fn"}                                         USA              CC                                            Workplace (ever)                                                              522                                                         0.80 (0.64--1.01)   No                                               ac(11)e
  Hanaoka et al., [@CIT0023]                                                                         Japan            P                                             Outside home, daily (current)[^j^](#TF41){ref-type="table-fn"}                77                                                          1.3 (0.9--1.9)      --                                               ac(11)
  Lissowska et al., [@CIT0109]                                                                       Poland           CC                                            Workplace (ever)                                                              1034                                                        1.05 (0.88--1.27)   --                                               ac(12)e
  Rollison et al., [@CIT0066]                                                                        USA              CC                                            Workplace (ever)                                                              124                                                         0.80 (0.49--1.32)   No                                               ac(8)
  Reynolds et al., [@CIT0062]                                                                        USA              P                                             Workplace (ever)                                                              1754                                                        1.02 (0.93--1.13)   --                                               ac(10)
  Luo et al., [@CIT0049]                                                                             USA              P                                             Workplace (adulthood)                                                         1660                                                        1.08 (0.97--1.19)   --                                               ac(10)e
  Xue et al., [@CIT0087]                                                                             USA              P                                             Workplace (current)                                                           2468                                                        0.94 (0.86--1.04)   d2                                               ac(16)e
  Anderson et al., [@CIT0002][^g^](#TF38){ref-type="table-fn"}^,^[^h^](#TF39){ref-type="table-fn"}   Canada           CC                                            Workplace (adulthood)                                                         909                                                         0.99 (0.82--1.20)   No                                               ac(1)e
  Tang et al., [@CIT0075]                                                                            China            CC                                            Workplace (adulthood)                                                         586                                                         1.23 (0.92--1.64)   --                                               ac(9)
                                                                                                                                                                    Workplace only (adulthood)                                                    474                                                         1.21 (0.84--1.74)   --                                               ac(9)
  Dossus et al., [@CIT0015]                                                                          Europe           P                                             Workplace (current)                                                           3286                                                        1.05 (0.98--1.13)   --                                               ac(11)e
                                                                                                                                                                    Workplace only (current)                                                      1117                                                        1.08 (0.95--1.23)                                                    ac(11)
  Li et al., [@CIT0046][^g^](#TF38){ref-type="table-fn"}^,^[^h^](#TF39){ref-type="table-fn"}         China            CC                                            Workplace (ever)                                                              877                                                         1.34 (1.01--1.77)   --                                               ac(10)e
                                                                                                                                                                    Workplace (ever) among those ever employed[^k^](#TF42){ref-type="table-fn"}   418                                                         1.19 (0.80--1.78)   No                                               ac(10)

Studies are in chronological order of the main publication.

Study type: P: prospective; CC: case-control.

Reference group is all lifelong nonsmokers unexposed to the given source, except where indicated by a reference to other notes. NOS implies ever in adulthood.

Number of breast cancers in lifelong nonsmokers in the analysis reported.

Dose response: "--" indicates dose response not studied, "No" indicates dose--response studied but no significant trend seen within the exposed groups, otherwise: d1: RRs are 0.9, 1.1, 1.1, 1.6 for 1--59, 60--179, 180--299, 300+ minutes of exposure per day (trend *p* \< 0.05); d2: RRs are 0.99, 0.87 for occasional, regular exposure at work (trend *p* \< 0.05).

Notes: a: adjusted for age of subject; c: adjusted for other confounding variables (see [Supplementary item 1](http://dx.doi.org/10.1080/08958378.2016.1210701)) -- number adjusted for shown in brackets; e: estimated from data reported; u: unadjusted.

See [Table 10](#t0010){ref-type="table"} for pre/post menopausal results for this analysis.

See [Supplementary item 2](http://dx.doi.org/10.1080/08958378.2016.1210701) for other subgroup results for this analysis.

Analysis restricted to women who had worked during the 5 years prior to interview.

Reference group is never exposed at home during life and not exposed daily outside the home at baseline.

Reference group is never exposed at work or at home who had ever been employed.

###### RR of breast cancer in lifelong nonsmoking women according to overall ETS exposure in adulthood.

  Study[^a^](#TF43){ref-type="table-fn"}                                                         Study location   Study type[^b^](#TF44){ref-type="table-fn"}   Source of exposure (timing)[^c^](#TF45){ref-type="table-fn"}               Number of breast cancers[^d^](#TF46){ref-type="table-fn"}   RR (95% CI)                          Dose response[^e^](#TF47){ref-type="table-fn"}   Notes[^f^](#TF48){ref-type="table-fn"}
  ---------------------------------------------------------------------------------------------- ---------------- --------------------------------------------- -------------------------------------------------------------------------- ----------------------------------------------------------- ------------------------------------ ------------------------------------------------ ----------------------------------------
  Smith et al., [@CIT0074]                                                                       UK               CC                                            Spouse/partner, work, other (adulthood)                                    94                                                          2.49 (0.87--7.16)                    No                                               ac(9)e
  Johnson et al., [@CIT0035][^g^](#TF49){ref-type="table-fn"}                                    Canada           CC                                            Home or workplace (NOS)                                                    606                                                         1.47 (1.06--2.04)                    --                                               ac(11)em
  Wartenberg et al., [@CIT0082]                                                                  USA              P                                             Any (current)Places other than home or workplace (current)                 669669                                                      1.0 (0.8--1.2)0.9 (0.7--1.2)         No--                                             ac(16)eac(16)
  Kropp & Chang-Claude,  [@CIT0037]                                                              Germany          CC                                            Home or workplace (adulthood)                                              197                                                         1.69 (1.16--2.45)                    No                                               ac(6)em
  Shrubsole et al., [@CIT0072]                                                                   China            CC                                            Home (ever) or workplace (last 5 years)[^i^](#TF51){ref-type="table-fn"}   864                                                         1.01 (0.79--1.28)                    --                                               ac(10)e
  Ahern et al., [@CIT0102]                                                                       USA              CC                                            Any (adulthood)[^j^](#TF52){ref-type="table-fn"}                           232                                                         0.86 (0.57--1.31)                    --                                               ac(5)em
  Reynolds et al., [@CIT0062]                                                                    USA              P                                             Any (adulthood)                                                            1754                                                        1.04 (0.91--1.19)                    --                                               ac(10)
  Luo et al., [@CIT0049]                                                                         USA              P                                             Home or workplace (adulthood)                                              1660                                                        1.01 (0.88--1.15)                    --                                               ac(10)e
  Xue et al., [@CIT0087][^g^](#TF49){ref-type="table-fn"}                                        USA              P                                             Home and work (adulthood)                                                  2109                                                        1.04 (0.94--1.16)                    No                                               ac(15)e
  Anderson et al., [@CIT0002][^g^](#TF49){ref-type="table-fn"}                                   Canada           CC                                            Any (adulthood)Social situations (adulthood)                               916907                                                      1.09 (0.83--1.42)1.14 (0.95--1.38)   NoNo                                             ac(1)eac(1)e
  Ilic et al., [@CIT0029]                                                                        Serbia           CC                                            Home or work (NOS)                                                         130                                                         1.57 (0.81--3.03)                    --                                               c(9)m
  Tang et al., [@CIT0075][^g^](#TF49){ref-type="table-fn"}^,^[^h^](#TF50){ref-type="table-fn"}   China            CC                                            Home or workplace (adulthood)                                              765                                                         1.47 (1.18--1.83)                    --                                               ac(9)
                                                                                                                                                                Home only (adulthood)                                                      615                                                         1.52 (1.17--1.97)                    --                                               ac(9)
                                                                                                                                                                Home and workplace (adulthood)                                             468                                                         1.76 (1.16--2.69)                    --                                               ac(9)
  Dossus et al., [@CIT0015]                                                                      Europe           P                                             Home or workplace (current)                                                3286                                                        1.06 (0.99--1.15)                    --                                               ac(11)e
                                                                                                                                                                Home only (current)                                                        844                                                         1.30 (1.07--1.59)                    --                                               ac(11)
                                                                                                                                                                Home and workplace (current)                                               832                                                         1.08 (0.87--1.32)                    --                                               ac(11)
  Li et al., [@CIT0046][^g^](#TF49){ref-type="table-fn"}^,^[^h^](#TF50){ref-type="table-fn"}     China            CC                                            Home or Work (adulthood)                                                   877                                                         1.35 (1.11--1.65)                    --                                               ac(9)

Studies are in chronological order of the main publication.

Study type: P: prospective; CC: case-control.

Reference group is all lifelong nonsmokers unexposed to the given source, except where indicated by a reference to other notes. NOS: not otherwise specified; taken to imply ever in adulthood. Where more than one estimate is available, the estimate closest to overall exposure in adulthood is listed first and is included in the Adulthood meta-analysis (see [Table 8](#t0008){ref-type="table"}).

Number of breast cancers in lifelong nonsmokers in the analysis reported.

Dose response: "--" indicates dose response not studied, "No" indicates dose--response studied but no significant trend seen within the exposed groups.

Notes: a: adjusted for age of subject; c: adjusted for other confounding variables (see [Supplementary item 1](http://dx.doi.org/10.1080/08958378.2016.1210701)) -- number adjusted for shown in brackets; e: estimated from data reported; m: included in principal meta-analysis (see [Table 9](#t0009){ref-type="table"}).

See [Table 10](#t0010){ref-type="table"} for pre/post menopausal results for this analysis.

See [Supplementary item 2](http://dx.doi.org/10.1080/08958378.2016.1210701) for other subgroup results for this analysis.

Analysis restricted to women who had worked during the 5 years prior to interview.

Reference group is never exposed in lifetime.

###### RR of breast cancer in lifelong nonsmoking women according to ETS exposure in childhood.

  Study[^a^](#TF53){ref-type="table-fn"}                                                             Study location   Study type[^b^](#TF54){ref-type="table-fn"}   Source of exposure[^c^](#TF55){ref-type="table-fn"}   Number of breast cancers[^d^](#TF56){ref-type="table-fn"}   RR (95% CI)                                          Dose response[^e^](#TF57){ref-type="table-fn"}   Notes[^f^](#TF58){ref-type="table-fn"}
  -------------------------------------------------------------------------------------------------- ---------------- --------------------------------------------- ----------------------------------------------------- ----------------------------------------------------------- ---------------------------------------------------- ------------------------------------------------ ----------------------------------------
  Sandler et al., [@CIT0070]                                                                         USA              CC                                            Mother                                                29                                                          0.92 (0.26--3.34)                                    --                                               ue
                                                                                                                                                                    Father                                                28                                                          0.91 (0.41--2.04)                                    --                                               ue
  Smith et al., [@CIT0074]                                                                           UK               CC                                            Any                                                   94                                                          1.18 (0.55--2.55)                                    No                                               ac(9)e
  Lash & Aschengrau, [@CIT0039]                                                                      USA              CC                                            At home                                               99                                                          2.40 (0.78--7.40)[^i^](#TF61){ref-type="table-fn"}   --                                               ac(8)e
  Johnson et al., [@CIT0035]                                                                         Canada           CC                                            At home                                               606                                                         1.24 (0.93--1.64)                                    --                                               ac(11)e
  Liu et al., [@CIT0048]                                                                             China            CC                                            At home                                               186                                                         1.16 (0.73--1.84)[^j^](#TF62){ref-type="table-fn"}   d1                                               ac(2)e
  Kropp & Chang-Claude, [@CIT0037]                                                                   Germany          CC                                            At home                                               197                                                         1.09 (0.77--1.55)                                    No                                               ac(6)e
  Lash & Aschengrau, [@CIT0040]                                                                      USA              CC                                            At home                                               224                                                         1.12 (0.82--1.54)                                    --                                               ac(9)e
  Bonner et al., [@CIT0003][^g^](#TF59){ref-type="table-fn"}                                         USA              CC                                            At home                                               525                                                         1.24 (0.96--1.60)                                    No                                               ac(11)e
  Lin et al., [@CIT0047]                                                                             Japan            P                                             At home                                               178                                                         1.24 (0.84--1.85)                                    --                                               ac(10)
  Pirie et al., [@CIT0059]                                                                           UK               P                                             Mother                                                2344                                                        0.96 (0.88--1.05)                                    --                                               ac(11)
                                                                                                                                                                    Father                                                2344                                                        1.03 (0.93--1.14)                                    --                                               ac(11)
  Rollison et al., [@CIT0066]                                                                        USA              CC                                            At home                                               123                                                         0.81 (0.47--1.40)                                    No                                               ac(8)
  Slattery et al., [@CIT0110]                                                                        USA              CC                                            Any                                                   1347                                                        No association                                       --                                               --
  Ahern et al., [@CIT0102]                                                                           USA              CC                                            Any[^k^](#TF63){ref-type="table-fn"}                  232                                                         1.20 (0.78--1.84)                                    --                                               ac(5)e
  Reynolds et al., [@CIT0064],[@CIT0062]                                                             USA              P                                             At home[^l^](#TF64){ref-type="table-fn"}              1150                                                        0.95 (0.84--1.07)                                    --                                               ac(11)e
                                                                                                                                                                    Any at age \<20                                       1313                                                        1.06 (0.94--1.19)                                    --                                               ac(10)
  Luo et al., [@CIT0049]                                                                             USA              P                                             Any                                                   1660                                                        1.08 (0.98--1.19)                                    --                                               ac(10)e
  Xue et al., [@CIT0087]                                                                             USA              P                                             Mother                                                2883                                                        0.88 (0.79--0.98)                                    --                                               ac(15)e
                                                                                                                                                                    Father                                                2883                                                        1.00 (0.93--1.08)                                    --                                               ac(15)e
  Anderson et al., [@CIT0002][^g^](#TF59){ref-type="table-fn"}^,^[^h^](#TF60){ref-type="table-fn"}   Canada           CC                                            At home[^m^](#TF65){ref-type="table-fn"}              912                                                         0.91 (0.75--1.10)                                    No                                               ac(1)e
                                                                                                                                                                    Any[^n^](#TF66){ref-type="table-fn"}                  912                                                         0.91 (0.74--1.13)                                    No                                               ac(1)e
  Chuang et al., [@CIT0009] reporting the  Dossus et al., [@CIT0015] study                           Europe           P                                             Parents[^o^](#TF67){ref-type="table-fn"}              3187                                                        0.98 (0.91--1.06)                                    No                                               ac(14)

Studies are in chronological order of the main publication.

Study type: P: prospective; CC: case-control.

Reference group is all lifelong nonsmokers unexposed to the given source.

Number of breast cancers in lifelong nonsmokers in the analysis reported.

Dose response: "--" indicates dose response not studied, "No" indicates dose--response studied but no significant trend seen within the exposed groups, otherwise: d1: RRs are 1.01, 2.50, 8.98 for 0, 1, 2, 3+ smokers at home (trend *p* \< 0.05), and 0.69, 1.31, 1.64, 1.74 for light, medium, heavy, very heavy exposure at home (trend *p* \< 0.05).

Notes: a: adjusted for age of subject; c: adjusted for other confounding variables (see [Supplementary item 1](http://dx.doi.org/10.1080/08958378.2016.1210701)) -- number adjusted for shown in brackets; e: estimated from data reported; u: unadjusted.

See [Table 10](#t0010){ref-type="table"} for pre/post menopausal results for this analysis.

See [Supplementary item 2](http://dx.doi.org/10.1080/08958378.2016.1210701) for other subgroup results for this analysis.

For exposure at age \< 12 years.

For exposure at age 1--9 years. For exposure at age 10--16 RR (95% CI) is 1.06 (0.67--1.68) with no significant dose--response.

Results were reported for parental, maternal and paternal smoking separately but are not included as based on ever smokers as well as never smokers.

Based on 6 years of follow-up only.

Exposure from others in household during ages 2--12 years only.

Exposure from any source during ages 13--19 years only.

Exposure from parents and other sources in childhood for two study centers only, based on only 10 years of follow-up.

###### RR of breast cancer in lifelong nonsmoking women according to total lifetime ETS exposure.

  Study[^a^](#TF68){ref-type="table-fn"}                                                              Study location   Study type[^b^](#TF69){ref-type="table-fn"}   Source of exposure[^c^](#TF70){ref-type="table-fn"}   Number of breast cancers[^d^](#TF71){ref-type="table-fn"}   RR (95% CI)                                          Dose response[^e^](#TF72){ref-type="table-fn"}   Notes[^f^](#TF73){ref-type="table-fn"}
  --------------------------------------------------------------------------------------------------- ---------------- --------------------------------------------- ----------------------------------------------------- ----------------------------------------------------------- ---------------------------------------------------- ------------------------------------------------ ------------------------------------------
  Smith et al., [@CIT0074]                                                                            UK               CC                                            Childhood, spouse/partner, work or other              94                                                          2.58 (0.96--6.94)                                    No                                               ac(9)e
  Morabia et al., [@CIT0056][^g^](#TF74){ref-type="table-fn"},[^h^](#TF75){ref-type="table-fn"}       Switzerland      CC                                            All[^i^](#TF76){ref-type="table-fn"}                  126                                                         3.2 (1.7--5.9)                                       No                                               ac(9)
  Johnson et al., [@CIT0035]                                                                          Canada           CC                                            Childhood, home or work                               606                                                         1.49 (1.02--2.18)                                    d1                                               ac(11)e
  Rookus et al., [@CIT0067][^h^](#TF75){ref-type="table-fn"}                                          Netherlands      CC                                            Home or work[^j^](#TF77){ref-type="table-fn"}         918                                                         1.2 (0.8--1.7)[^l^](#TF79){ref-type="table-fn"}      --                                               c(?)m
  Kropp & Chang-Claude,  [@CIT0037][^h^](#TF75){ref-type="table-fn"}                                  Germany          CC                                            Childhood, home or work                               197                                                         1.59 (1.06--2.39)                                    No                                               ac(6)
  Hanaoka et al., [@CIT0023]                                                                          Japan            P                                             Childhood, home or outside home                       162                                                         1.1 (0.8--1.6)                                       --                                               ac(11)
  Sillanpää et al., [@CIT0073][^h^](#TF75){ref-type="table-fn"}                                       Finland          CC                                            Home or work (ever, by years exposed)                 363                                                         0.85 (0.62--1.16)                                    --                                               ac(6)m
  Lissowska et al., [@CIT0109][^g^](#TF74){ref-type="table-fn"}^,^[^h^](#TF75){ref-type="table-fn"}   Poland           CC                                            Home (at different times) or work (for each job)      1034                                                        1.11 (0.85--1.46)                                    No                                               ac(12)
  Zhu et al., [@CIT0091][^g^](#TF74){ref-type="table-fn"}^,^[^h^](#TF75){ref-type="table-fn"}         China            P                                             Lifetime (NOS)                                        390                                                         Not available                                        d2                                               n
  Pirie et al., [@CIT0059][^g^](#TF74){ref-type="table-fn"},[^h^](#TF75){ref-type="table-fn"}         UK               P                                             Parents/spouse                                        2344                                                        0.98 (0.88--1.09)                                    --                                               ac(11)
  Rollison et al., [@CIT0066]                                                                         USA              CC                                            Cohabitants (lifetime)                                122                                                         1.06 (0.56--2.02)                                    No                                               ac(8)
  Slattery et al., [@CIT0110][^g^](#TF74){ref-type="table-fn"}^,^[^h^](#TF75){ref-type="table-fn"}    USA              CC                                            Childhood, home or outside home                       1347                                                        1.05 (0.88--1.27)                                    No                                               ac(9)[^l^](#TF79){ref-type="table-fn"}em
  Ahern et al., [@CIT0102]                                                                            USA              CC                                            Parents, home or work                                 232                                                         0.91 (0.54--1.55)                                    --                                               ac(5)e
  Reynolds et al., [@CIT0062]                                                                         USA              P                                             Childhood, home, work or social                       1754                                                        1.10 (0.94--1.30)                                    No                                               ac(10)
  Young et al., [@CIT0089][^m^](#TF80){ref-type="table-fn"}                                           Canada           CC                                            Childhood, home or work                               2751                                                        0.97 (0.88--1.08)                                    --                                               a
  Chilian-Herrera et al., [@CIT0008][^g^](#TF74){ref-type="table-fn"}                                 Mexico           CC                                            Lifetime home or work                                 \(504\)                                                     3.34 (2.38--4.68)[^n^](#TF81){ref-type="table-fn"}   d3                                               ac(?)m
  Conlon et al., [@CIT0012][^h^](#TF75){ref-type="table-fn"}                                          Canada           CC                                            Lifetime home or work                                 129                                                         1.15 (0.61--2.18)                                    No                                               emu
  De Silva et al., [@CIT0013]                                                                         Sri Lanka        CC                                            Any (NOS)                                             100                                                         2.96 (1.53--5.75)[^o^](#TF82){ref-type="table-fn"}   --                                               ac(7)m
  Luo et al., [@CIT0049][^h^](#TF75){ref-type="table-fn"}                                             USA              P                                             Childhood, home or work                               1660                                                        1.09 (0.92--1.29)                                    No                                               ac(10)
  Rosenberg et al., [@CIT0068][^g^](#TF74){ref-type="table-fn"}                                       USA              P                                             Home (ages 0--30) or work (ages 21--30)               771                                                         1.18 (0.98--1.42)                                    --                                               ac(13)m
  Dossus et al., [@CIT0015]                                                                           Europe           P                                             Childhood; home or work (at baseline)                 3597                                                        1.10 (1.01--1.20)                                    --                                               ac(11)

Studies are in chronological order of the main publication.

Study type: P: prospective; CC: case-control.

Reference group is all lifelong nonsmokers unexposed to the given source, except where indicated by a reference to other notes.

Number of breast cancers in lifelong nonsmokers in the analysis reported. Number in bracket: number of cases in the study, including ever-smokers (number in never-smokers unknown).

Dose response: "--" indicates dose response not studied, "No" indicates dose--response studied but no significant trend seen within the exposed group, otherwise: d1: for premenopausal breast cancer RRs are 1.2, 1.8, 2.0, 3.3, 2.9 for 1--6, 7--16, 17--21, 22--35, 36+ combined years exposure at home and at work (trend *p* \< 0.05). No trend seen for postmenopausal breast cancer. d2: RRs are 1, 1.02, 1.42, 1.72 for never exposed, \<2.0, 2.0 to \< 4.0, 4.0 + h/day average lifetime exposure (trend *p*\<0.0001). Trend over the exposed categories probably also significant but data provided are insufficient to check. No information was given on numbers of unexposed subjects, so overall RR (CI) could not be estimated. d3: a significant positive trend was reported (*p* \< 0.001), but it was not stated whether this was within the exposed groups only.

Notes: a: adjusted for age of subject; c: adjusted for other confounding variables (see [Supplementary item 1](http://dx.doi.org/10.1080/08958378.2016.1210701)) -- number adjusted for is shown in brackets with "?" representing an unknown number of adjustment variables; e: estimated from data reported; m: included in principal meta-analysis (see [Table 9](#t0009){ref-type="table"}); n: adjustment not specified; u: unadjusted.

See [Table 10](#t0010){ref-type="table"} for pre/post menopausal results for this analysis.

See [Supplementary item 2](http://dx.doi.org/10.1080/08958378.2016.1210701) for other subgroup results for this analysis.

Exposed for at least 1 h/day ETS exposure from any source for at least 12 consecutive months during life.

Exposed daily to the smoke of home-smokers or colleagues during at least 20 years or if someone smoked daily in their bedroom during more than 1 year.

RR was noted to be no greater for first exposure before first pregnancy.

Adjusted for factors shown in [Supplementary item 1](http://dx.doi.org/10.1080/08958378.2016.1210701) plus menopausal status and ethnicity during estimation of RR.

Combines data from the study by Anderson et al. ([@CIT0002]) plus another study. Not included in principal meta-analysis.

RR given for "t3" versus "t1", but no explanation of groupings given although it was stated that reference group consisted of never active smokers without history of passive smoking.

An alternative result of 2.90 (1.49--5.63), adjusted for eight confounding variables, was also reported by this study.

###### Meta-analyses of breast cancer risk for six indices of ETS exposure.

                                                                                             Fixed-effect        Random-effects      Heterogeneity                  
  ------------------------------------------------------------------------------------- ---- ------------------- ------------------- --------------- ---- --------- --------
  All studies                                                                                                                                                        
   Spouse (2)[^f^](#TF88){ref-type="table-fn"}                                          14   1.08 (1.00--1.16)   1.14 (1.00--1.28)   25.69           13   \<0.05    \<0.1
   Home (2 and 3)[^g^](#TF89){ref-type="table-fn"}                                      34   1.05 (1.02--1.09)   1.09 (1.03--1.16)   70.05           33   \<0.001   \<0.01
   Workplace (4)[^h^](#TF90){ref-type="table-fn"}^,^[^i^](#TF91){ref-type="table-fn"}   15   1.03 (0.99--1.07)   1.03 (0.97--1.10)   25.87           14   \<0.05    NS
   Adulthood (5)[^i^](#TF91){ref-type="table-fn"}^,^[^j^](#TF92){ref-type="table-fn"}   14   1.09 (1.04--1.14)   1.13 (1.04--1.22)   28.96           13   \<0.01    \<0.05
   Childhood (6)[^i^](#TF91){ref-type="table-fn"}                                       17   0.99 (0.95--1.03)   1.00 (0.95--1.06)   21.27           16   NS        \<0.1
   Total (7)                                                                            20   1.09 (1.04--1.14)   1.22 (1.09--1.37)   84.11           19   \<0.001   \<0.05
    Excluding outlier[^k^](#TF93){ref-type="table-fn"}                                  19   1.07 (1.02--1.12)   1.12 (1.03--1.22)   41.32           18   \<0.01    \<0.01
  Prospective studies[^l^](#TF94){ref-type="table-fn"}                                                                                                               
   Spouse (2)[^f^](#TF88){ref-type="table-fn"}                                          7    1.04 (0.95--1.15)   1.07 (0.93--1.22)   8.28            6    NS         
   Home (2 and 3)[^g^](#TF89){ref-type="table-fn"}                                      15   1.01 (0.97--1.06)   1.02 (0.97--1.07)   17.86           14   NS         
   Workplace (4)[^h^](#TF90){ref-type="table-fn"}^,^[^i^](#TF91){ref-type="table-fn"}   6    1.02 (0.98--1.07)   1.01 (0.95--1.09)   9.77            5    \<0.1      
   Adulthood (5)[^i^](#TF91){ref-type="table-fn"}^,^[^j^](#TF92){ref-type="table-fn"}   5    1.04 (0.99--1.10)   1.04 (0.99--1.80)   0.57            4    NS         
   Childhood (6)[^i^](#TF91){ref-type="table-fn"}                                       6    0.98 (0.94--1.02)   0.98 (0.92--1.04)   9.48            5    \<0.1      
   Total (7)                                                                            6    1.07 (1.02--1.13)   1.07 (1.02--1.12)   4.23            5    NS         
  Case-control studies                                                                                                                                               
   Spouse (2)[^f^](#TF88){ref-type="table-fn"}                                          7    1.13 (1.01--1.26)   1.24 (1.00--1.55)   16.39           6    \<0.05     
   Home (2 and 3)[^g^](#TF89){ref-type="table-fn"}                                      19   1.14 (1.07--1.22)   1.18 (1.06--1.31)   42.04           18   \<0.01     
   Workplace (4)[^h^](#TF90){ref-type="table-fn"}^,^[^i^](#TF91){ref-type="table-fn"}   9    1.06 (0.97--1.15)   1.08 (0.95--1.23)   15.55           8    \<0.05     
   Adulthood (5)[^i^](#TF91){ref-type="table-fn"}^,^[^j^](#TF92){ref-type="table-fn"}   9    1.28 (1.16--1.41)   1.28 (1.11--1.49)   15.10           8    \<0.1      
   Childhood (6)[^i^](#TF91){ref-type="table-fn"}                                       11   1.08 (0.97--1.20)   1.05 (0.97--1.15)   8.60            10   NS         
   Total (7)                                                                            14   1.12 (1.05--1.21)   1.40 (1.12--1.75)   78.89           13   \<0.001    
   Excluding outlier[^k^](#TF93){ref-type="table-fn"}                                   13   1.07 (0.99--1.15)   1.24 (1.05--1.48)   37.07           12   \<0.001    

Source table shown in parentheses.

*N*: number of studies in meta-analysis.

df: degrees of freedom.

*p* expressed as \<0.001, \<0.01, \<0.05, \<0.1 or NS (*p* ≥ 0.1).

Egger's test for publication bias.

Index includes "partner". Where a study provides more than one estimate, the first RR cited is selected. This ensures that exposure to spouse (ever) is chosen for preference where multiple results are available.

The Home meta-analysis selects estimates for cohabitant from [Table 3](#t0003){ref-type="table"} for studies for which they are available and spousal estimates from [Table 2](#t0002){ref-type="table"} where they were not. Thus for Wartenberg et al. ([@CIT0082]) the estimate cited in [Table 3](#t0003){ref-type="table"} has been selected rather than that cited in [Table 2](#t0002){ref-type="table"}. For Smith et al. ([@CIT0074]) and Nishino et al. ([@CIT0058]), where the estimates in [Table 3](#t0003){ref-type="table"} were for cohabitant other than the spouse, the spousal estimate cited in [Table 2](#t0002){ref-type="table"} has been selected. Only the first estimates for a study given in [Table 2](#t0002){ref-type="table"} or [Table 3](#t0003){ref-type="table"} are considered for selection.

Index includes "not home" exposure.

First RR cited for each study in the table.

Index includes "home or workplace" exposure.

Excluding the estimate of 3.34 (95% CI 2.38--4.68) from Chilian-Herrera et al. ([@CIT0008]). Outliers were not found for other indices.

Including nested case-control studies.

As shown in [Table 2](#t0002){ref-type="table"}, 14 studies provide RRs specifically for the spouse (or partner), with significantly (*p* \< 0.05) increased risks seen in two (Morabia et al., [@CIT0056]; Tong et al., [@CIT0076]). Combining these 14 studies (and selecting the RR for spouse ever smoked from Wartenberg et al., [@CIT0082]) gives a fixed-effect meta-analysis estimate of 1.08 (95% CI 1.00--1.16), which is marginally significant. There is significant heterogeneity, mainly due to the RRs of 3.1 for Morabia et al. ([@CIT0056]) and 0.58 for Nishino et al. ([@CIT0058]). Random-effect meta-analysis increases the estimate to 1.14 and it remains marginally significant (95% CI 1.00--1.28).

[Table 3](#t0003){ref-type="table"} presents RRs for ETS exposure at home, other than spouse-only exposure, from 23 studies. Taking results from either [Table 2](#t0002){ref-type="table"} or [Table 3](#t0003){ref-type="table"} and preferring the more inclusive estimate for those three studies which provided results for both tables, statistically significantly increased RRs and/or dose-related trends are seen in six studies (Lash & Aschengrau, [@CIT0039]; Li et al., [@CIT0046]; Liu et al., [@CIT0048]; Morabia et al., [@CIT0056]; Tang et al., [@CIT0075]; Tong et al., [@CIT0076]) but many studies show no increase, and Lin et al. ([@CIT0047]) reported a significantly reduced risk for past exposure to cohabitant\'s smoking. The fixed-effect estimate for ETS exposure at home, based on 34 studies, is 1.05 (95% CI 1.02--1.09) while the random-effects estimate is 1.09 (1.03--1.16). Again, Morabia et al. ([@CIT0056]) makes a large contribution to the significant (*p* \< 0.001) heterogeneity.

The results shown in [Table 4](#t0004){ref-type="table"} are for workplace (or not-home) exposure. Three studies (Li et al., [@CIT0046]; Liu et al., [@CIT0048]; Shrubsole et al., [@CIT0072]) show significant positive RRs or trends, while Xue et al. ([@CIT0087]) reported a significantly negative dose--response. The RRs are significantly heterogeneous, with estimates varying from 0.80 for Wartenberg et al. ([@CIT0082]), Bonner et al. ([@CIT0003]) and Rollison et al. ([@CIT0066]) to about 1.50 for Smith et al. ([@CIT0074]) and Liu et al. ([@CIT0048]). No significant overall effect is evident (see [Table 8](#t0008){ref-type="table"}).

[Table 5](#t0005){ref-type="table"} shows results for overall ETS exposure in adulthood. Fourteen studies give estimates either for any adult exposure or for home and/or workplace exposure. Based on the first estimate cited in [Table 5](#t0005){ref-type="table"} for studies giving multiple estimates, significantly increased RRs are seen in four studies (Johnson et al., [@CIT0035]; Kropp & Chang-Claude, [@CIT0037]; Li et al., [@CIT0046]; Tang et al., [@CIT0075]) and, overall, a significant elevation is seen, based on fixed-effect (1.09, 95% CI 1.04--1.14) or random-effects (1.13, 1.04--1.22) analysis. Again, the RRs are heterogeneous (*p* \< 0.01).

The results for childhood exposure ([Table 6](#t0006){ref-type="table"}) are from 18 studies. Most RRs are close to 1.0 and none are significantly increased, although Liu et al. ([@CIT0048]) reported a significant positive trend. Xue et al. ([@CIT0087]) reported a significantly negative association with exposure to smoking by the mother but not with exposure to the father. Based on the first RR given in [Table 6](#t0006){ref-type="table"} for studies with multiple RRs available, no significant overall effect is evident, with the fixed-effect (0.99, 0.95--1.03) and random-effects (1.00, 0.95--1.06) estimates both close to 1.

Twenty one studies give results ([Table 7](#t0007){ref-type="table"}) for total lifetime exposure (studies considering exposure both during childhood and during adulthood). Significant increases and/or dose-related trends are seen in seven studies (Chilian-Herrera et al., [@CIT0008]; De Silva et al., [@CIT0013]; Dossus et al., [@CIT0015]; Johnson et al., [@CIT0035]; Kropp & Chang-Claude, [@CIT0037]; Morabia et al., [@CIT0056]; Zhu et al., [@CIT0091]). One of these studies (Zhu et al., [@CIT0091]), only reported as an abstract, found a dose-related positive trend but gave insufficient detail to allow derivation of an overall RR. Although the remaining 20 RR estimates are heterogeneous (*p* \< 0.001), 16 of these are above 1, and the overall estimate is significant, using either fixed-effect (1.09, 95% CI 1.04--1.14) or random-effects (1.22, 1.09--1.37) meta-analysis.

Total lifetime exposure was the only index of exposure considered in [Table 8](#t0008){ref-type="table"} for which evidence (*p* \< 0.001) of an outlier was seen. This was for the study by Chilian-Herrera et al. ([@CIT0008]), where removing this high RR of 3.34 (95% CI 2.38--4.68) reduced the random-effects estimate from 1.22 (1.09--1.37) to 1.12 (1.03--1.22).

Some evidence of publication bias (*p* \< 0.05) was seen for three of the six indices considered in [Table 8](#t0008){ref-type="table"}. This was generally due to small studies tending to give above average RRs.

[Table 8](#t0008){ref-type="table"} also includes results of meta-analyses separately by study type. It is evident that there is much clearer evidence of an association from case-control studies where the random effects RRs always exceed those from the prospective (including nested case-control) studies. For workplace and childhood exposure no significant increase in risk is seen for case-control or prospective studies, while for spousal, home and adulthood exposure, a significant increase in risk is seen only for case-control studies. Only for total exposure is an increase seen for both study types, though that seen for prospective studies (RR 1.07, 95% CI 1.03--1.12) is quite weak, based on individual study estimates of 0.98, 1.09, 1.10, 1.10, 1.10 and 1.18. Heterogeneity between estimates is not significant for any index for prospective studies, but is significant for case-control studies for spousal, home, workplace and total exposure.

Principal meta-analysis {#s3C}
-----------------------

A principal meta-analysis was conducted using one RR from each study, for the exposure most equivalent to the classic index "spouse ever smoked." The RRs used, 14 from [Table 2](#t0002){ref-type="table"}, 20 from [Table 3](#t0003){ref-type="table"}, four from [Table 5](#t0005){ref-type="table"} and seven from [Table 7](#t0007){ref-type="table"}, are marked with an "m" in the notes column of these tables.

Overall, these studies give a fixed-effect estimate of 1.07 (95% CI 1.04--1.10). However, there is marked heterogeneity (*p* \< 0.001), mainly due to high RRs in three studies (Chilian-Herrera et al., [@CIT0008]; Kropp & Chang-Claude, [@CIT0037]; Morabia et al., [@CIT0056]). Consequently, the random-effects estimate is higher (1.15, 1.07--1.23) (see [Table 9](#t0009){ref-type="table"} and [Figure 1](#F0001){ref-type="fig"}).

![Forest plot of random-effects RRs and 95% CIs from the principal meta-analysis -- all studies. Studies are shown in order of increasing RR estimate. Lines representing CIs that are marked ♦ have not been shown to their full length. See the CI values given.](iiht_a_1210701_f0001_c){#F0001}

###### Meta-analyses of breast cancer risk for principal index of ETS exposure (spouse ever smoked or nearest equivalent)[^a^](#TF95){ref-type="table-fn"}.

                                                                Fixed-effect        Random-effects           Heterogeneity[^b^](#TF96){ref-type="table-fn"}                   
  -------------------------------------------------------- ---- ------------------- ------------------------ ------------------------------------------------ ---- ---------- --------
  All studies                                                                                                                                                                  
   All                                                     45   1.07 (1.04--1.10)   1.15 (1.07--1.23)        139.64                                           44   \<0.001    \<0.05
   Excluding outlier[^g^](#TF101){ref-type="table-fn"}     44   1.06 (1.03--1.09)   1.11 (1.05--1.17)        95.68                                            43   \<0.001    \<0.01
   Excluding abstracts[^h^](#TF102){ref-type="table-fn"}   43   1.06 (1.03--1.09)   1.11 (1.05--1.18)        95.63                                            42   \<0.001     
   N.America[^i^](#TF103){ref-type="table-fn"}             21   1.04 (1.00--1.09)   1.12 (1.02--1.23)        66.89                                            20   \<0.001     
   Asia                                                    13   1.20 (1.11--1.30)   1.21 (1.04--1.42)        37.56                                            12   \<0.001     
   Europe                                                  11   1.06 (0.99--1.12)   1.12 (0.98--1.27)        25.77                                            10   \<0.01      
                                                                                    (Between continents      9.42                                             2    \<0.01)     
   \>500 cases                                             19   1.04 (1.01--1.08)   1.07 (1.02--1.13)        33.17                                            18   \<0.05      
   \<500 cases[^j^](#TF104){ref-type="table-fn"}           23   1.14 (1.04--1.25)   1.22 (1.04--1.43)        57.91                                            22   \<0.001     
                                                                                    (Between study sizes     3.02                                             1    NS)         
   9+ confounders[^k^](#TF105){ref-type="table-fn"}        21   1.04 (1.00--1.07)   1.07 (1.00--1.15)        53.98                                            20   \<0.001     
   \<9 confounders[^l^](#TF106){ref-type="table-fn"}       21   1.15 (1.07--1.23)   1.19 (1.07--1.32)        34.43                                            20   \<0.05      
                                                                                    (Between adjustments     6.80                                             1    \<0.01)     
   Prospective[^m^](#TF107){ref-type="table-fn"}           16   1.02 (0.98--1.06)   1.02 (0.97--1.08)        19.69                                            15   NS          
   Case-control                                            29   1.18 (1.12--1.25)   1.26 (1.13--1.41)        100.78                                           28   \<0.001     
                                                                                    (Between study types     19.18                                            1    \<0.001)    
   Detailed questions[^n^](#TF108){ref-type="table-fn"}    24   1.05 (1.01--1.09)   1.14 (1.04--1.25)        95.21                                            23   \<0.001     
   Not detailed questions                                  21   1.12 (1.05--1.19)   1.16 (1.05--1.28)        41.37                                            20   \<0.01      
                                                                                    (Between detail levels   3.06                                             1    \<0.1)      
  Prospective studies[^m^](#TF107){ref-type="table-fn"}                                                                                                                        
   Detailed questions[^n^](#TF108){ref-type="table-fn"}    8    1.00 (0.96--1.05)   1.00 (0.96--1.05)        8.12                                             7    NS          
   Not detailed questions                                  8    1.09 (0.99--1.19)   1.10 (0.98--1.25)        9.23                                             7    NS          
                                                                                    (Between detail levels   2.33                                             1    NS)         
   Follow-up ≤10 years                                     8    1.02 (0.96--1.08)   1.02 (0.95--1.10)        8.41                                             7    NS          
   Follow-up 11+ years                                     8    1.02 (0.97--1.07)   1.03 (0.95--1.11)        11.27                                            7    NS          
                                                                                    (Between length groups   0.00                                             1    NS)         
  Case-control studies                                                                                                                                                         
   Detailed questions[^n^](#TF108){ref-type="table-fn"}    16   1.21 (1.13--1.31)   1.30 (1.09--1.54)        68.17                                            15   \<0.001     
   Not detailed questions                                  13   1.14 (1.06--1.24)   1.21 (1.05--1.39)        31.42                                            12   \<0.01      
                                                                                    (Between detail levels   1.19                                             1    NS)         
   Population controls                                     20   1.13 (1.06--1.21)   1.25 (1.08--1.44)        83.13                                            19   \<0.001     
   Other types of controls                                 9    1.29 (1.17--1.43)   1.31 (1.14--1.51)        12.91                                            8    NS          
                                                                                    (Between control types   4.75                                             1    \<0.05      

Based on RRs marked with an "m" in the notes column in [Tables 2, 3, 5 and 7](#t0002 t0003 t0005 t0007){ref-type="table"}.

Heterogeneity relates to variation between studies within subgroup, except for the results given in italics which relate to heterogeneity between subgroups.

Nnumber of studies in meta-analysis.

df: degrees of freedom.

*p* expressed as \<0.001, \<0.01, \<0.05, \<0.1 or NS (*p* ≥ 0.1).

Egger's test for publication bias.

Excluding the estimate of 3.34 (95% CI 2.38--4.68) from Chilian-Herrera etal. ([@CIT0008]).

Also excluding the estimate of 1.03 (95% CI 0.81--1.31) from Woo etal. ([@CIT0086]).

Includes one study in Mexico.

The number of cases in nonsmokers was not known for three studies (see [Tables 3](#t0003){ref-type="table"} and [7](#t0007){ref-type="table"}).

Analyses that adjusted for age and 9+ potential confounders. Three studies were excluded from this and from the \<9 confounders analysis because the number of confounding variables adjusted for other than age was not clear (see [Supplementary item 1](http://dx.doi.org/10.1080/08958378.2016.1210701)).

This analysis includes estimates that were adjusted for 9+ potential confounders but not for age.

Including nested case-control studies.

A study is categorized as asking detailed questions if it included questions on exposure in childhood, at home in adulthood (spousal or more general home exposure) and other adult exposure, such as workplace exposure. The studies are identified in [Table 1](#t0001){ref-type="table"} by having an asterisk against ETS sources.

Chilian-Herrera et al. ([@CIT0008]) was again a significant (*p* \< 0.001) outlier, and as shown in [Table 9](#t0009){ref-type="table"}, removing it from the meta-analysis reduced the random-effects estimate from 1.15 (95% CI 1.07--1.23) to 1.11 (1.05--1.17). This study was one of only two for which the available results came from an abstract. Also removing the other (Woo et al., [@CIT0086]) had little further effect, the random-effects estimate becoming 1.11 (1.05--1.18).

There was some evidence of publication bias (*p* \< 0.05). This is illustrated in [Figure 2](#F0002){ref-type="fig"}, where the logarithm of the RR is plotted against the standard error of the RR estimate. The tendency for studies with high standard errors, which would be based on relatively few cases, to report high RRs, is evident, and is consistent with the idea that smaller studies may not report results unless they find a positive relationship.

![Funnel plot of each RR from the principal meta-analysis against its standard error. RRs are shown on a logarithmic scale. The vertical line at RR 1.15 represents the overall meta-analysis RR.](iiht_a_1210701_f0002_c){#F0002}

To study further possible sources of heterogeneity, RRs were compared by various study characteristics.

### Continent {#s3C1}

Although there is some evidence of an effect for all three continents, with a significant increase seen in North America (random-effects estimate 1.12, 95% CI 1.02--1.23, based on *n* = 21 estimates) and in Asia (1.21, 1.04--1.42, *n* = 13), and an almost significant increase seen in Europe (1.12, 0.98--1.27, *n* = 11), there is heterogeneity (*p* \< 0.01) between continents due to the higher estimate for Asia. There is significant (*p* \< 0.01) heterogeneity within each continent.

### Study size {#s3C2}

The results from the 19 studies involving over 500 cases show some evidence of heterogeneity (*p* \< 0.05) and increase in risk (random-effects RR 1.07, 95% CI 1.02--1.13). The 23 smaller studies also show significant (*p* \< 0.001) heterogeneity, and an increase in risk (random-effects RR 1.22, 1.04--1.43). Although estimates are higher for the smaller than the larger studies, this difference is not significant.

### Adjustment for potential confounding variables {#s3C3}

Studies were divided, approximately equally, into those that had adjusted for age and nine or more other potential confounding variables and those that had not adjusted for age or had adjusted for eight or fewer other variables. In both groups, there is significant heterogeneity. In the 21 studies that had adjusted for age and nine or more other potential confounding variables, there was no significant evidence of an association of ETS with breast cancer (random-effects RR 1.07, 95% CI 0.999--1.15) but, in the group that had not adjusted for age or had adjusted for eight or fewer other variables, there was a significant relationship, random-effects RR 1.19, 1.07--1.32). The difference in RR by number of confounding variables adjusted for was significant at *p* \< 0.05.

We also investigated the effect of adjustment in specific studies, by comparing most-adjusted and least-adjusted RR estimates for the principal exposure index. In fact, only eight studies (De Silva et al., [@CIT0013]; Hanaoka et al., [@CIT0023]; Ilic et al., [@CIT0029]; Lin et al., [@CIT0047]; Luo et al., [@CIT0049]; Smith et al., [@CIT0074]; Wartenberg et al., [@CIT0082]; Xue et al., [@CIT0087]) presented results allowing such comparison. Effects of additional adjustment were generally minimal, with the overall most-adjusted/least-adjusted ratio estimated as 1.01 (95% CI 0.96--1.07).

### Study type {#s3C4}

There is a clear difference (*p* \< 0.001) between the study types. Thus, the 16 prospective studies show no significant evidence of an effect or of heterogeneity (see [Figure 3](#F0003){ref-type="fig"}), with no evidence that RR estimates varied by length of follow-up. However, the 29 case-control studies do show an association (random-effects RR 1.26, 95% CI 1.13--1.41) and are significantly heterogeneous (*p* \< 0.001) (see [Figure 4](#F0004){ref-type="fig"}). This is consistent with nearly all the significant (*p* \< 0.05) positive associations shown in [Tables 2--7](#t0002 t0007){ref-type="table"}, being in case-control studies. The estimate was very similar (1.25, 1.08--1.44) when attention was restricted to the 20 case-control studies using population controls.

![Forest plot of random-effects RRs and 95% CIs from the principal meta-analysis -- prospective studies. Studies are shown in order of increasing RR estimate.](iiht_a_1210701_f0003_b){#F0003}

![Forest plot of random-effects RRs and 95% CIs from the principal meta-analysis -- case-control studies. *Note*: Studies are shown in order of increasing RR estimate. Lines representing CIs that are marked ♦ have not been shown to their full length. See the CI values given.](iiht_a_1210701_f0004_c){#F0004}

### Detailed questions {#s3C5}

Of the 45 studies for which an RR estimate is available for spousal smoking or nearest equivalent, 24 were based on studies which asked detailed ETS exposure questions. As shown in [Table 9](#t0009){ref-type="table"}, there was no evidence of any variation in risk whether or not detailed questions were asked. This was true when all studies were considered, and also in separate analyses by study type. It is notable that, in the eight studies which were both prospective in design and asked detailed questions, which might be regarded as providing the best evidence on effects of ETS, there was no evidence of heterogeneity or of an increased risk, with the meta-analysis estimate very close to 1. Six of these estimates came from studies published since our earlier review (Lee & Hamling, [@CIT0045]).

RR estimates by menopausal status {#s3D}
---------------------------------

[Table 10](#t0010){ref-type="table"} presents results by menopausal status for 25 studies. The Reynolds study presented results for ages \<50 and 50+ at diagnosis and for menopausal status at baseline. As the follow-up was for 10 years, the first of these is used as the estimate of menopausal status at diagnosis. Four of these 25 studies (Hanaoka et al., [@CIT0023]; Rosenberg et al., [@CIT0068]; Wells, [@CIT0084]; Woo et al., [@CIT0086]) show significantly higher RRs in premenopausal women, with no increase seen for postmenopausal women. In three more studies (Alberg et al., [@CIT0001]; Delfino et al., [@CIT0014]; Johnson et al., [@CIT0035]) the pattern is similar, but the variation is not significant. In Chilian-Herrera et al. ([@CIT0008]), the RRs for both pre- and postmenopausal women are significantly increased, but the RR in premenopausal women is much higher. In Pirie et al. ([@CIT0059]), the RR for premenopausal women is significantly decreased, while no association is seen for peri- or postmenopausal women. Li et al. ([@CIT0046]) reports a non-significantly increased risk for premenopausal women and a significantly increased RR for postmenopausal women. The remaining studies showed no evidence of variation in risk according to menopausal status.

###### RR of breast cancer in lifelong nonsmoking women according to ETS exposure; by menopausal status.

  Study[^a^](#TF109){ref-type="table-fn"}                                       Exposure index (timing)[^b^](#TF110){ref-type="table-fn"}   Subgroup                                    RR (95% CI)                                           Heterogeneity[^c^](#TF111){ref-type="table-fn"}   Notes[^d^](#TF112){ref-type="table-fn"}
  ----------------------------------------------------------------------------- ----------------------------------------------------------- ------------------------------------------- ----------------------------------------------------- ------------------------------------------------- -----------------------------------------
  Wells, [@CIT0084] reporting the Sandler et al., [@CIT0070] study              Spouse (ever)                                               PremenopausalPostmenopausal                 7.11 (1.35--37.5)0.89 (0.36--2.22)                    4.62 (1), *p* \< 0.05                             ue
  Morabia et al., [@CIT0113]                                                    All (ever)[^e^](#TF118){ref-type="table-fn"}                Premenopausal                               2.21 (1.03--4.75)                                     0.03 (1), NS                                      ae
                                                                                                                                            Postmenopausal                              2.04 (1.19--3.48)                                                                                        
  Delfino et al., [@CIT0014]                                                    Cohabitant (ever)                                           Premenopausal                               2.69 (0.91--8.00)                                     2.01 (1), NS                                      ac~1~
                                                                                                                                            Postmenopausal                              1.01 (0.45--2.27)                                                                                        
  Johnson et al., [@CIT0035]                                                    Home or work (ever)                                         Premenopausal                               2.3 (1.2--4.6)                                        2.64 (1), NS                                      ac~2~f
                                                                                                                                            Postmenopausal                              1.2 (0.8--1.8)                                                                                           
  Woo et al., [@CIT0086]                                                        Cohabitant (current)                                        Premenopausal                               2.78 (1.37--5.63)                                     8.50 (1), *p* \< 0.01                             u
                                                                                                                                            Postmenopausal                              0.91 (0.71--1.18)                                                                                        
  Alberg et al., [@CIT0001]                                                     Spouse (ever)                                               Premenopausal                               1.83 (0.32--10.57)                                    0.37 (1), NS                                      ue
                                                                                                                                            Postmenopausal                              1.01 (0.45--2.24)                                                                                        
  Gammon et al., [@CIT0018]                                                     Cohabitant (ever)                                           PremenopausalPostmenopausal                 1.21 (0.78--1.90)0.93 (0.68--1.29)                    0.89 (1), NS                                      ac~2~
  Shrubsole et al., [@CIT0072]                                                  Spouse (ever)                                               Premenopausal                               1.0 (0.8--1.3)                                        0.24 (1), NS                                      ac~2~g
                                                                                                                                            Postmenopausal                              0.9 (0.6--1.2)                                                                                           
  Bonner et al., [@CIT0003]                                                     Cohabitant (ever)                                           Premenopausal                               1.35 (0.78--2.33)                                     0.35 (1), NS                                      ac~2~
                                                                                                                                            Postmenopausal                              1.10 (0.74--1.64)                                                                                        
                                                                                Workplace (ever)                                            Premenopausal                               0.63 (0.41--0.96)                                     1.79 (1), NS                                      ac~2~
                                                                                                                                            Postmenopausal                              0.89 (0.68--1.18)                                                                                        
                                                                                At home (childhood)                                         Premenopausal                               1.35 (0.84--2.18)                                     0.17 (1), NS                                      ac~2~
                                                                                                                                            Postmenopausal                              1.20 (0.89--1.63)                                                                                        
  Hanaoka et al., [@CIT0023]                                                    Cohabitant (ever)[^f^](#TF113){ref-type="table-fn"}         Premenopausal                               1.6 (0.9--2.7)                                        4.71 (1), *p* \< 0.05                             ac~2~h
                                                                                                                                            Postmenopausal                              0.7 (0.4--1.1)                                                                                           
  Lissowska et al., [@CIT0108]                                                  Home or work (ever)                                         Premenopausal                               1.55 (0.81--2.97)                                     1.61 (1), NS                                      ac~3~ei
                                                                                                                                            Postmenopausal                              0.97 (0.71--1.34)                                                                                        
  Millikan et al., [@CIT0112] reporting the Mechanic et al., [@CIT0053] study   Cohabitant (ever)[^g^](#TF114){ref-type="table-fn"}         Premenopausal                               1.5 (0.8--2.8)                                        0.27 (1), NS                                      ac~4~
                                                                                                                                            Postmenopausal                              1.2 (0.7--2.2)                                                                                           
  Zhu et al., [@CIT0091]                                                        All (ever)                                                  Premenopausal                               Data not shown                                        NA                                                j
                                                                                                                                            Postmenopausal                              Data not shown                                                                                           
  Roddam et al., [@CIT0065]                                                     Spouse (ever)                                               Premenopausal                               0.83 (0.59--1.17)                                     0.31 (1), NS                                      ac~5~
                                                                                                                                            Peri/postmenopausal                         1.51 (0.19--12.2)                                                                                        
  Pirie et al., [@CIT0059]                                                      Parents (ever)/                                             Premenopausal                               0.54 (0.30--0.99)                                     3.80 (2), NS                                      ac~2~
                                                                                spouse (current)                                            Postmenopausal                              0.98 (0.87--1.10)                                                                                        
                                                                                                                                            Perimenopausal                              1.03 (0.69--1.55)                                                                                        
  Slattery et al., [@CIT0110]                                                   Any (ever)                                                  Pre/perimenopausal                          1.13 (0.85--1.50)                                     0.42 (1), NS                                      ac~6~e
                                                                                                                                            Postmenopausal                              1.00 (0.79--1.27)                                                                                        
  Reynolds et al., [@CIT0063]                                                   Cohabitant (ever)                                           Age (at diagnosis/end of follow-up) \< 50   1.05 (0.76--1.45)                                     0.96 (1), NS                                      ac~3~ef
                                                                                                                                            ≥50                                         0.88 (0.76--1.01)                                                                                        
                                                                                                                                                                                                                                                                                                 
  Reynolds et al., [@CIT0064]                                                   Cohabitant (ever)                                           Pre/perimenopausal (at baseline)            0.93 (0.71--1.22)                                     0.01 (1), NS                                      ac~2~f
                                                                                                                                            Postmenopausal (at baseline)                0.92 (0.78--1.08)                                                                                        
  Chilian-Herrera et al., [@CIT0008]                                            Home or work (ever)                                         Premenopausal                               4.75 (2.58--7.35)[^h^](#TF115){ref-type="table-fn"}   2.31 (1), NS                                      ac~3~
                                                                                                                                            Postmenopausal                              2.83 (1.87--4.28)[^h^](#TF115){ref-type="table-fn"}                                                      
  Egan et al., [@CIT0105], reporting the Xue et al., [@CIT0087] study           Home and work (adulthood)                                   Premenopausal                               Data not shown                                        NS                                                ac~2~
                                                                                                                                            Postmenopausal                              Data not shown                                                                                           
  Anderson et al., [@CIT0002][^i^](#TF116){ref-type="table-fn"}                 Cohabitant (adulthood)                                      Premenopausal                               1.07 (0.78--1.47)                                     0.01 (1), NS                                      ac~3~e
                                                                                                                                            Postmenopausal                              1.09 (0.86--1.39)                                                                                        
                                                                                Cohabitant (childhood)                                      Premenopausal                               0.81 (0.58--1.12)                                     0.67 (1), NS                                      ac~3~e
                                                                                                                                            Postmenopausal                              0.96 (0.75--1.21)                                                                                        
                                                                                Work (adulthood)                                            Premenopausal                               0.98 (0.71--1.35)                                     0.01 (1), NS                                      ac~3~e
                                                                                                                                            Postmenopausal                              1.00 (0.79--1.27)                                                                                        
                                                                                Social situations                                           Premenopausal                               1.21 (0.88--1.66)                                     0.18 (1), NS                                      ac~3~e
                                                                                (adulthood)                                                 Postmenopausal                              1.11 (0.88--1.41)                                                                                        
                                                                                Any (teenage)                                               Premenopausal                               0.98 (0.69--1.39)                                     0.23 (1), NS                                      ac~3~e
                                                                                                                                            Postmenopausal                              0.88 (0.68--1.14)                                                                                        
                                                                                Any (adulthood)                                             Premenopausal                               1.18 (0.78--1.77)                                     0.28 (1), NS                                      ac~3~e
                                                                                                                                            Postmenopausal                              1.02 (0.71--1.45)                                                                                        
  Rosenberg et al., [@CIT0068]                                                  Childhood, home or workplace (ever)                         Premenopausal                               1.42 (1.09--1.85)                                     4.52 (1),                                         ac~3~
                                                                                                                                            Postmenopausal                              0.92 (0.68--1.24)                                     *p* \< 0.05                                        
  Tang et al., [@CIT0075]                                                       Home or workplace (adulthood)                               Premenopausal                               1.54 (1.14--2.07)                                     0.02 (1), NS                                      ac~2~
                                                                                                                                            Postmenopausal                              1.49 (1.03--2.16)                                                                                        
  Nishino et al., [@CIT0057]                                                    Spouse (ever)                                               Premenopausal                               0.88 (0.61--1.29)                                     2.03 (1), NS                                      ac~3~
                                                                                                                                            Postmenopausal                              1.22 (0.95--1.56)                                                                                        
  Li et al., [@CIT0046]                                                         Home or workplace (adulthood)                               Premenopausal                               1.18 (0.93--1.50)                                     4.11 (1), *p* \< 0.05                             ac~3~
                                                                                                                                            Postmenopausal                              1.83 (1.29--2.60)                                                                                        
                                                                                Home exposure (adulthood)                                   Premenopausal                               1.10 (0.84--1.43)                                     4.45 (1), *p* \< 0.05                             ac~7~
                                                                                                                                            Postmenopausal                              1.80 (1.24--2.61)                                                                                        
                                                                                Workplace (ever)                                            Premenopausal                               1.07 (0.67--1.70)                                     0.83 (1), NS                                      ac~8~
                                                                                                                                            Postmenopausal                              1.70 (0.70--4.08)                                                                                        
  Wada et al., [@CIT0079]                                                       Spousal (ever)                                              Premenopausal                               1.32 (0.59--2.93)                                     0.27 (1), NS                                      ac~3~e
                                                                                                                                            Postmenopausal                              1.80 (0.77--4.21)                                                                                        

Studies are in chronological order of the main publication.

Reference group is all lifelong nonsmokers unexposed to the given source, except where indicated by a reference to other notes.

The chi-squared statistic is shown with the degrees of freedom in brackets and then the *p*-value. NS=*p* ≥ 0.1. NA = not available.

Notes: a: adjusted for age; c: adjusted for other confounding variables as indicated below; c~1~: family history of breast cancer; c~2~: all variables listed in [Supplementary item 1](http://dx.doi.org/10.1080/08958378.2016.1210701) except the subgroup variable; c~3~: all variables listed in [Supplementary item 1](http://dx.doi.org/10.1080/08958378.2016.1210701); c~4~: race, age at menarche, age at first full-term pregnancy, parity, family history of breast cancer, benign breast biopsy, alcohol; c~5~: region, parity and oral contraceptive use; c~6~: all variables listed in [Supplementary item 1](http://dx.doi.org/10.1080/08958378.2016.1210701), and ethnicity; c~7~: all variables listed in [Supplementary item 1](http://dx.doi.org/10.1080/08958378.2016.1210701) except residence and study stage, subjects exposed at work only excluded; c~8~: all variables listed in [Supplementary item 1](http://dx.doi.org/10.1080/08958378.2016.1210701) except residence and study stage, subjects exposed at home only excluded; u: unadjusted; e: estimated from data reported.

RRs for adult and childhood exposure separately also did not vary significantly by menopausal status or age at diagnosis (data not shown).

RRs for workplace exposure and for combined spousal and workplace exposure also did not vary significantly by menopausal status (data not shown).

RRs for exposure other than at home and for any exposure were also both significantly higher for premenopausal than postmenopausal women. Non-home (2.3 versus 0.4, Heterogeneity *p* \< 0.001), Any (2.6 versus 0.7, Heterogeneity *p* \< 0.01).

For each menopausal status, dose response analysis (\<100, 101--200, \>200 h/day-years) was non-significant (*p* value for trend 0.08 for premenopausal, 0.74 for postmenopausal).

Results quoted only as "The \[hazard ratio\] for \[secondhand smoke\] was higher among premenopausal than postmenopausal women."

Exposed for at least 1 h/day ETS exposure from any source for at least 12 consecutive months during life.

Reference group is never exposed at home during life and not exposed daily outside the home at baseline.

Based on subset of 352 cases.

RR given for "t3" versus "t1" but no explanation of groupings given although it was stated that reference group consisted of never active smokers without history of passive smoking.

An earlier abstract (Anderson et al., [@CIT0103]) refers to having studied 11 candidate genes, including the five for which results were given in the later paper (Anderson et al., [@CIT0002]) and shown above, concluding that the relationship between passive smoke exposure and breast cancer was found to be modified by certain genetic variants, but without giving any detailed results.

As shown in [Table 11](#t0011){ref-type="table"}, meta-analysis of the 23 studies providing RR estimates by menopausal status shows no effect of ETS in postmenopausal women. Exposure is, however, associated with a significant increase in premenopausal women. However, there is marked heterogeneity (*p* \< 0.001) and the random-effects estimate (1.36, 95% CI 1.15--1.60) is considerably higher than the fixed-effects estimate (1.24, 1.14--1.35). Some evidence of a higher risk in premenopausal women is also seen when the ratio, for each study, of the premenopausal to postmenopausal RR was meta-analyzed. The random-effects estimate for premenopausal women is little changed, to 1.38 (1.18--1.61), if RRs for two additional case-control studies of young women (Kropp & Chang-Claude, [@CIT0037]; Smith et al., [@CIT0074]) are included, on the basis that all, or virtually all, of the women would have been premenopausal. We have not included results for age \<50 years from two prospective studies (Hirayama, [@CIT0024]; Wartenberg et al., [@CIT0082]) as these relate to age at baseline, and many of the cases of breast cancer would have occurred in postmenopausal women.

###### Meta-analyses of breast cancer risk in relation to ETS exposure by menopausal status[^a^](#TF123){ref-type="table-fn"}.

                                                                                     Fixed-effect        Random-effects      Heterogeneity                    
  ----------------------------------------------- ----------------------------- ---- ------------------- ------------------- --------------- ---- ----------- --------
  All                                             Premenopausal                 23   1.24 (1.14--1.35)   1.36 (1.15--1.60)   68.33           22   \<0.001     \<0.05
                                                  Postmenopausal                23   1.04 (0.98--1.10)   1.12 (1.00--1.25)   58.28           22   \<0.001     \<0.1
                                                  Ratio pre/post                23   1.14 (1.01--1.28)   1.19 (1.00--1.42)   40.28           22   \<0.05      NS
  Prospective[^f^](#TF128){ref-type="table-fn"}   Premenopausal                 7    1.27 (1.07--1.50)   1.28 (0.92--1.77)   15.48           6    \<0.05       
                                                  Postmenopausal                7    0.93 (0.86--1.01)   0.95 (0.90--1.00)   4.95            6    NS           
                                                  Ratio pre/post                7    1.32 (1.06--1.63)   1.35 (0.89--2.05)   16.77           6    \<0.05       
  Case-control                                    Premenopausal                 16   1.23 (1.12--1.36)   1.40 (1.14--1.71)   52.77           15   \<0.001      
                                                  Postmenopausal                16   1.19 (1.09--1.30)   1.23 (1.06--1.44)   37.64           15   \<0.01       
                                                  Ratio pre/post                16   1.07 (0.93--1.23)   1.11 (0.92--1.33)   21.03           15   NS           
  Heterogeneity by study type                     PremenopausalPostmenopausal                                                0.0815.69       11   NS\<0.001    
                                                  Ratio pre/post                                                             2.48            1    NS           

Based on data in [Table 10](#t0010){ref-type="table"}.

*N*: number of studies in meta-analysis.

df: degrees of freedom.

*p* expressed as \<0.001, \<0.01, \<0.05, \<0.1 or NS (*p* ≥ 0.1).

Egger's test for publication bias.

Including nested case-control studies.

[Table 11](#t0011){ref-type="table"} also includes separate results for prospective and case-control studies. In postmenopausal women, RRs are markedly higher in case-control studies than in prospective studies (*p* \< 0.001). Heterogeneity by study type is not evident in premenopausal women, where some evidence of an increased risk is seen for both study types, though significant only for case-control studies.

RR estimates by other factors {#s3E}
-----------------------------

[Supplementary item 2](http://dx.doi.org/10.1080/08958378.2016.1210701) presents RRs for various subgroups other than menopausal status which are available in the source papers. These include results by factors such as age, occupation, a range of genetic markers and aspects of the cancer, such as hormone receptor status.

Generally, these results provide little evidence of any significant variation in RR by genetic status (NAT1, NAT2, p53, SULT1A1, MnSOD, XRCC1, XPD, NER, IL6, ESR1, CYP2E1, UGT1A7, PARP1 and other unspecified genes), by age or by any other factor considered. Significant variation (at *p* \< 0.05) was only noted in Wartenberg et al. ([@CIT0082]) by product smoked by the spouse among those whose spouse was a former smoker; in Lash & Aschengrau ([@CIT0040]) for first exposure being before or after first pregnancy, where first exposure before first pregnancy gave a significant reduction in estimated risk; in Gammon et al. ([@CIT0018]) by BMI, where the variation was not systematic and may well be due to chance; in Zhu et al. ([@CIT0091]) by use of oral contraceptives and by use of other female hormones; and in Anderson et al. ([@CIT0002]) by CYP2E1 genotype in postmenopausal women exposed to passive smoke as a teenager. Li et al. ([@CIT0046]) report a range of analyses by combinations of subgroups, among which the estimates for smoker-years exposure in postmenopausal women and for total smoker-years exposure when considering cases with hormone receptor status ER+/PR + show statistically significant heterogeneity (results not shown). Many of the subgroups were only investigated in a few studies, while in those that were studied more often no consistent patterns were evident. For example, six studies provided RRs for ETS exposure separately for NAT2 slow and fast acetylators. No significant differences were noted, with three studies giving higher RRs for slow acetylators and three giving higher RRs for fast acetylators.

Discussion {#s4}
==========

Comparison with our previous review {#s4A}
-----------------------------------

It is of interest to compare the results of this update, based on 47 studies, with those of our earlier review (Lee & Hamling, [@CIT0045]) based on 22 studies. For the principal index of exposure, most closely equivalent to "spouse ever smoked", the existence of an association is confirmed, with the random-effects RR of 1.15 (95% CI 1.07--1.23) quite similar to the earlier estimate of 1.12 (1.02--1.24). For the associations with exposure from the spouse (or partner) and with at home exposure generally, non-significant associations previously evident have become marginally significant with the greater number of studies, with random-effects RRs now 1.14 (1.00--1.28) for spousal exposure and 1.09 (1.03--1.16) for at-home exposure. However, associations remain non-significant for workplace exposure (1.03, 0.97--1.03) and childhood exposure (1.00, 0.95--1.06). As before, a significant association is seen with any adult exposure (1.13, 1.04--1.22) and also with total exposure, though the magnitude of this relationship has weakened, from 1.54 (1.17--2.04) based on six RR estimates, to 1.22 (1.09--1.37) based on 20. The strength of the association with menopausal status has also weakened, with the RR for the ratio of pre- to postmenopausal status reducing from 1.50 (1.12--2.00) based on 10 estimates, to a just non-significant 1.19 (1.00--1.42) based on 23. (Note that, in the above, and in the rest of this discussion, meta-analysis RRs cited are unless stated otherwise, always random-effects.)

As before, heterogeneity is clearly evident in nearly all of these associations. Some similarities and differences are again evident in the analyses based on the principal index investigating relationships with various study characteristics. While both now and earlier there was clear variation by continent, the pattern of results has changed. Earlier these were due to a high RR for Europe of 1.50 (95% CI 1.14--1.97) based on five estimates, but this has declined considerably to 1.12 (0.98--1.27), based on 11. In contrast, the estimate for Asia has increased, from 1.09 (0.90--1.33) based on six studies, to 1.21 (1.04--1.42), which is now higher than the estimates for North America and Europe. As before, there is a tendency for estimates to be smaller for larger studies (based on at least 500 cases) and for studies adjusting for age and at least nine confounding variables.

A striking similarity between the two sets of analyses is the finding that there is essentially no association between ETS and breast cancer in prospective or nested case-control studies, where the exposure would have been determined prior to disease onset, the only exception being for total exposure where the RR was 1.07 (95% CI 1.02--1.12), based on six estimates. In our earlier analysis, the overall RR from nine prospective studies for the principal ETS exposure index was 1.02 (0.93--1.10) and there was concern that the great majority of these came from studies which had not determined detailed exposure histories. In the present analysis, which includes results from many more studies with detailed histories, no association is again seen, with the RR again 1.02, though with somewhat narrower 95% CI of 0.97--1.08. In the present analyses, we defined a study as having a detailed exposure history if it asked about childhood ETS exposure as well as about exposure in adulthood both in the home and outside. No significant differences were seen between studies with or without detailed questions on exposure, and it was notable that the combined results from the eight prospective studies that did ask detailed questions gave a RR estimate for the principal index of 1.003 (0.96--1.05), not suggestive of any relationship.

Conclusions from other reviews {#s4B}
------------------------------

As noted in the introduction, various reviews of the evidence have been conducted in the last 10 years or so. These include the California EPA (California Environmental Protection Agency, [@CIT0005]; Johnson, [@CIT0033]; Miller et al., [@CIT0055]), the Canadian Expert Group (Collishaw et al., [@CIT0011]; Johnson et al., [@CIT0036]), the IARC (International Agency for Research on Cancer, [@CIT0031]; Secretan et al., [@CIT0071]), the Oxford Group (Pirie et al., [@CIT0059]) and the 2014 report of the US Surgeon General ([@CIT0078]). There is broad agreement between these reviews and ours in various aspects of the evidence. These include the following: the associations of ETS exposure and of active smoking with breast cancer are both weak; there is little or no evidence of any association with ETS exposure in prospective studies; there is no evidence of an association with childhood ETS exposure; there is considerable evidence of heterogeneity; and associations are much more clearly evident for premenopausal women than for postmenopausal women. Despite this there is marked variation between the reviews in how the results are to be interpreted. At one extreme, the California EPA and the Canadian Expert Group argue that the data show a causal relationship in premenopausal women, while at the other the Oxford Group argue that the evidence is consistent with ETS exposure having no effect on breast cancer risk. Intermediate positions are occupied by the IARC, who do not include breast cancer in the cancers for which sufficient evidence of an effect of ETS exposure has been demonstrated, and by the US Surgeon General. In their report (US Surgeon General, [@CIT0078]), they regarded the evidence as "suggestive but not sufficient to infer a causal relationship" of breast cancer with tobacco smoke, active smoking and exposure to secondhand smoke.

In assessing the results in terms of a causal relationship, various issues have to be taken into account. These are outlined in the sections that follow, in which we refer, where appropriate, to the views expressed in the various reviews.

Selection of studies for inclusion {#s4C}
----------------------------------

We have restricted attention to studies of lifelong nonsmokers, an approach which is traditional in studies of ETS, and is the one also generally used in published reviews.

Study weaknesses {#s4D}
----------------

None of the studies had serious weaknesses, as defined in Lee ([@CIT0042]). However, many studies had less serious weaknesses. These include the following:Small number of cases, with some of the RRs being based on less than 100 cases, with consequent variability of the estimate.Prospective studies of some years duration determining ETS exposure and other risk factors only at baseline, so not allowing for possible changes in exposure. As shown in [Table 1](#t0001){ref-type="table"}, there were 12 prospective studies involving nine years of follow-up or more, and in none of them were repeat interviews carried out.Use of control groups with diseases that may be associated with ETS exposure. This will bias the RR for ETS and breast cancer downward where this association is positive, and upward where it is negative.General reliance on ETS exposure reported by the subject (or, in Lash & Aschengrau, [@CIT0039],[@CIT0040], by the next-of-kin for some subjects), with no confirmation by cotinine or other biomarker, or by data reported by other individuals such as the spouse or coworker.Failure in many studies to restrict attention to married subjects when analyzing spousal exposure or to control for household size when analyzing household exposure. Thus, for example, for spousal smoking, comparing exposed women who by definition must be married, with unexposed women who may or may not be, leads to the possibility of confounding by variables that differ between married and unmarried women.

We did not exclude any of the studies from analysis due to these weaknesses because their assessment is subjective and therefore open to criticism, although in some analyses we demonstrated the effect of excluding results which were clear outliers on statistical grounds. This was only relevant to the study by Chilian-Herrera et al. ([@CIT0008]), where excluding its high RR reduced the overall estimates for total ETS exposure and for the principal meta-analysis, though not affecting the significance of these associations.

While most reviews use data from all available studies, some meta-analyses have been reported restricted to "better" studies. Thus, the California Environmental Protection Agency ([@CIT0005]) limited some analyses to "Most informative studies" which restricted attention to those studies that included a historical determination of lifetime exposure to tobacco smoke, used a referent population that was unexposed to the multiple sources of exposure considered, and which considered exposures at different "windows of susceptibility". Essentially, this implies preference for estimates of lifetime total exposure over individual source estimates.

Also, the 2014 report by the US Surgeon General ([@CIT0078]) reported some results for the "most comprehensive measure of secondhand smoke ... excluding studies with design or analysis issues". It was notable that, while the California EPA's exclusions tended to increase the observed association of ETS with breast cancer, the US Surgeon General's tended to reduce it. It is likely that neither set of exclusions were derived blind of the results.

### Plausibility {#s4D1}

While the 2014 report by the US Surgeon General ([@CIT0078]) regards the evidence as "sufficient to identify mechanisms by which cigarette smoking may cause breast cancer", they do not regard the evidence that active smoking increases breast cancer risk as more than suggestive. Though the California Environmental Protection Agency ([@CIT0005]) regards the evidence on active smoking as demonstrating a causal relationship, there still remains the problem of understanding how the claimed increases in risk from active smoking and ETS exposure might be so similar.

One possible reason given by the Canadian Expert Panel (Collishaw et al., [@CIT0011]) for the similarity in risks was the relative difference in anti-estrogenic effects between the two sources of tobacco exposure, whereby the anti-estrogenic effects associated with active smoking might depress the level of breast cancer risk related to tobacco smoke in active smokers, but not be strong enough in women exposed to ETS to depress their tobacco-related risk. Another explanation put forward was the existence of a low threshold effect where pathways become saturated at a relatively low level of exposure to tobacco smoke, in the range normally associated with ETS exposure, with further exposure not resulting in further risk. As pointed out by the IARC (International Agency for Research on Cancer, [@CIT0031]), the theory that "active smoking may have counterbalancing protective and differential effects on breast cancer risk that in combination, produced little or no association, whereas secondhand tobacco smoking may only have an adverse effect on risk" suffers from the weakness of a "lack of direct evidence identifying the mechanism by which active smoking may cause the proposed \[protective\] antiestrogenic effect".

In contrast, some reviews have not concluded that there is a demonstrated effect of active smoking or ETS exposure on breast cancer risk. Thus, the IARC (International Agency for Research on Cancer, [@CIT0030]) concluded that there is evidence suggesting a lack of carcinogenicity of tobacco smoking for female breast cancer, noting a combined analysis from 53 studies (Collaborative Group on Hormonal Factors in Breast Cancer, [@CIT0010]) which showed that a weak association can be explained by confounding by alcohol consumption and in the same year, the US Surgeon General ([@CIT0077]) also concluded that the evidence is "suggestive of no causal relationship." Although, in 2014, the US Surgeon General ([@CIT0078]) referred to "multiple lines of evidence" supporting "biologic plausibility", and that the evidence of a causal relationship was "suggestive" for both active smoking and ETS exposure, they still regarded it as "not sufficient to infer a causal relationship".

If indeed active smoking has little or no effect on breast cancer risk, is it plausible that ETS exposure might have a true effect on the risk? In our earlier review (Lee & Hamling, [@CIT0045]) we pointed out that the denominators are not the same in the two RR calculations, with the risk in smokers generally compared to that in all nonsmokers, whether ETS exposed or not. We went on to present calculations showing that the observation that risks are similar in smokers and nonsmokers, but higher in ETS exposed than in ETS unexposed nonsmokers, implies that the increase in risk relative to the totally unexposed group is greater as a result of ETS exposure than as a result of active smoking.

It has been argued that, as the mix of carcinogens in sidestream tobacco smoke is different from the mix in mainstream smoke inhaled during active smoking, it is not essential for the causality decision on ETS that active smoking causes breast cancer (Anderson et al., [@CIT0002]; Miller, [@CIT0054]). However, it still seems implausible that ETS exposure might have a greater effect on risk than active smoking. One reason is that exposure to smoke constituents is in general very much higher from smoking than from ETS. Another is that smokers are exposed to higher levels of ETS exposure than are nonsmokers, partly as they are more likely to mix with other smokers, and partly as they are exposed to ETS from their own cigarettes. To fit the observations one would have to argue that ETS exposure is carcinogenic to the breast, but smoking is anti-carcinogenic. *A priori* it seems more plausible to us that no true effects of smoking or ETS exposure exist, with observed increases in risk associated with ETS seen in some analyses resulting from one or more of the biases possible in epidemiological studies.

While genetic differences in susceptibility to tobacco-induced cancers have been put forward as a possible reason for the observed results (Alberg et al., [@CIT0001]; Anderson et al., [@CIT0002]; Chuang et al., [@CIT0009]; Conlon et al., [@CIT0012]; Dossus et al., [@CIT0015]; Johnson & Glantz, [@CIT0034]; Luo et al., [@CIT0049]; Mechanic et al., [@CIT0053]; Sillanpää et al., [@CIT0073]; Tang et al., [@CIT0075]), we are unaware of any consistent evidence of an increased risk of ETS associated breast cancer in relation to any gene.

### Consistency {#s4D2}

The 45 estimates for the principal exposure index are significantly (*p* \< 0.001) heterogeneous. Study type is a major source of the heterogeneity, with the RR for prospective studies not significantly elevated at 1.02 (95% CI 0.97--1.08) but clearly raised for case-control studies at 1.26 (1.13--1.41), the difference by study type being highly significant (*p* \< 0.001). While heterogeneity for the case-control study RRs (*p* \< 0.001) still remains, it is interesting to note that it is not evident for the prospective study RRs. Other sources of heterogeneity observed are by continent (*p* \< 0.01) with RRs higher for Asia (1.21, 1.04--1.42) than for Europe (1.12, 0.98--1.27) or North America (1.12, 1.02--1.23), and by extent of adjustment for potential confounding variables (*p* \< 0.01), with the RR higher for studies adjusting for fewer variables (1.19, 1.07--1.32) than for studies adjusting for more (1.07, 1.00--1.15).

As noted earlier, there is also inconsistency between results for different ETS exposure indices, with no evidence of an association for childhood or for workplace ETS exposure, but more evidence for ETS exposure indices involving multiple sources of exposure.

The US Surgeon General ([@CIT0078]) noted that, while the evidence "is relatively consistent for a real effect of active smoking on risk for breast cancer", it is "less consistent for passive exposure to smoking, with marked differences between case-control and cohort studies and greater sensitivity to exclusions for design and analysis issues, sample size and extreme estimates".

Assessment of ETS exposure and recall bias {#s4E}
------------------------------------------

In our previous review (Lee & Hamling, [@CIT0045]), we noted that a number of case-control studies which asked very detailed lifetime ETS exposure histories had reported high RRs, and we suggested that these may be unusually open to recall bias. We noted that it seemed "unlikely that anyone will actually have had no ETS exposure in their life, and because memory of low exposures is difficult and subjective, there must be concern about the accuracy of RR estimates that depend greatly on which subjects happen to be classified in this 'unexposed' reference group. If a relatively low level of actual ETS exposure is more likely to be reported by cases, perhaps in an effort to explain their disease, than by controls, such differential recall may cause substantial bias to the estimated effects of ETS."

At that time there were hardly any prospective studies which collected detailed ETS exposure histories, but that is not the situation now. Interestingly, the analyses shown in [Table 9](#t0009){ref-type="table"} indicate that there is no material difference between RRs for studies using detailed ETS questions and for those that did not, and that this is so when prospective and case-control studies are considered separately.

While results from case-control studies which asked detailed exposure questions have been regarded by some (e.g. California Environmental Protection Agency, [@CIT0005]; Johnson, [@CIT0033]) as contributing greatly to the evidence, it is interesting to note the complete lack of association for prospective studies which asked detailed questions (RR 1.00, 95% CI 0.96--1.05).

As noted by Reynolds ([@CIT0061]), "measurement error is a problem in all studies, and is likely a larger problem for secondhand smoking than for active smoking". In this context it is worth pointing out that it is questionable whether in fact detailed questions which are reliant on accuracy of recall of lifetime exposure histories actually give more reliable answers than do simple questions likely to be quite accurately answered, though not incorporating all sources of exposure. While there is abundant evidence that asking whether the spouse smokes is associated with clearly elevated cotinine levels (e.g. Lee, [@CIT0043]), such objective validation of exposure is not available for more complex measures.

Crucial to the opinions of the reviews is their opinion on the relevance of recall bias. It is clear that the authors of the California EPA and the Canadian Expert Group do not regard the elevated risks seen in case-control studies as materially affected by recall bias. Thus, Johnson ([@CIT0033]) notes that reviews of recall bias in studies of ETS and lung cancer, and ETS and heart disease "have concluded that recall bias is unlikely to have had an important effect on those observed relationships" and the California Environmental Protection Agency ([@CIT0005]) regard such bias as unlikely "since a possible link of smoking or ETS to breast cancer is not commonly known to the public nor previously accepted by the scientific community".

In contrast, other reviewers clearly regard recall bias as highly relevant. Thus, the US Surgeon General ([@CIT0078]) noted in 2014 that "cohort studies are generally regarded as providing stronger evidence then case-control studies for causality because they satisfy the temporality criterion that the measurement of exposure precede the ascertainment of the outcome", while the Oxford Group (Pirie et al., [@CIT0059]) is more emphatic about the importance of recall bias. As noted in the introduction, they emphasize the lack of effect seen in prospective studies and consider that the results from the case-control studies may have been "distorted" by recall bias. They noted that the evidence for breast cancer following ETS exposure is similar to that for breast cancer following induced abortion, where no increased risk is seen when the data on induced abortion are collected before the cancer, but an increase is seen when they are collected afterwards. It is also interesting to note that the IARC (International Agency for Research on Cancer, [@CIT0031]) included a discussion on recall bias giving reasons why case-control studies with the most complete information on lifetime exposure to ETS may be most susceptible to recall bias, pointing out that "it is easier to report smoking by a parent or spouse than it is to remember exposure from other sources that possibly occurred many years ago in daily life".

Can this discrepancy of views be resolved? Some of the individual publications have attempted to obtain information on the magnitude of recall bias. Two studies (Conlon et al., [@CIT0012]; Morabia et al., [@CIT0056]) have asked questions concerning worry about ETS exposure, but similarity of response in cases and controls does not exclude the possibility that, regardless of worry, the cases were readier to give full details of their ETS exposure, as the study may have been more important to them than to the controls.

The evidence of Johnson et al. ([@CIT0035]) relating to recall bias derives from the observation that "when lung cancer risk was assessed using the same target control group, observed lung cancer risks associated with passive smoking were consistent with those in the lung cancer-passive smoking literature". But the lung cancer RR of 1.2 had a very large variability, with a 95% CI of 0.7--2.1, and furthermore related to an exposure index "6 or more years of adult residential exposure to passive smoking" that did not involve all the recorded sources of ETS exposure.

Delfino et al. ([@CIT0014]) avoided recall bias by recruiting cases and controls from those with suspicious breast masses, and collecting questionnaire data prior to biopsy diagnosis. Although this approach excluded recall bias, and the study found no association of ETS with breast cancer, it is doubtful whether the controls are representative of the population at large.

Considered together, this evidence adds little to the debate about recall bias.

Dose--response relationship {#s4F}
---------------------------

Assessment of the existence of a dose--response relationship is made difficult by the lack of data from a number of studies, and by the heterogeneous nature of the results that are available. Corresponding to the 45 estimates for the principal ETS exposure index, dose--response data within ETS exposed subjects were available for only 20 studies. Three studies showed a statistically significant positive trend (Li et al., [@CIT0046]; Liu et al., [@CIT0048]; Tong et al., [@CIT0076]). The study by Chilian-Herrera et al. ([@CIT0008]) reported a significant positive trend, but gave no further details, not making it clear if the trend had been calculated within the exposed groups only. No significant trend was seen in the remaining 16 studies. Among the 15 which provided RRs by level of exposure, the RRs tended to increase with increasing exposure in nine, to decrease in five, and to show no relationship in one.

There appears to be more evidence of a dose response for total exposure. However, some trends reported as significant in the source publications (e.g. Morabia et al., [@CIT0056]; Reynolds et al., [@CIT0062]) are based on data including the unexposed group, with RRs similar in the ETS exposed groups. Our [Table 7](#t0007){ref-type="table"} identifies only three studies as reporting a significant dose response within the exposed groups. One is Chilian-Herrera et al. ([@CIT0008]), as noted above, and another is Johnson et al. ([@CIT0035]), which found a trend only in premenopausal women. The third is Zhu et al. ([@CIT0091]), which actually provided insufficient data to formally calculate the trend within the exposed groups,

Overall, it is not apparent that consideration of dose--response data, which the 2014 report by the US Surgeon General ([@CIT0078]) regards as "not definitive", adds to the case for or against ETS exposure as a possible cause of breast cancer.

Misclassification of the subject\'s smoking status {#s4G}
--------------------------------------------------

Misclassification of the subject\'s smoking may be a relevant biasing factor in studies of ETS and lung cancer (Lee et al., [@CIT0044]) because lung cancer risk is markedly increased in smokers. However, inclusion in ETS and breast cancer studies of a few true smokers with a possibly slightly increased risk of breast cancer should have little or no biasing effect. This is not mentioned as a relevant issue in any of the reviews.

Confounding {#s4H}
-----------

Although ([see supplementary item 1](http://dx.doi.org/10.1080/08958378.2016.1210701)) the majority of studies have adjusted for an extensive list of potential confounding variables, not all did so. We therefore investigated confounding by comparing RR estimates for the principal index of ETS exposure in studies which had adjusted for an above average and below average number of variables. This showed weaker evidence of an association (*p* \< 0.01) in studies that adjusted for age plus nine variables or more (RR 1.07, 95% CI 1.00--1.15), than for studies that adjusted for eight variables or fewer (1.19, 1.07--1.32). Although this may suggest that the association may have arisen partly due to limited attention to confounding in some studies, this inference is not straightforward. The studies that adjusted for nine variables or more included all the six large prospective studies (Dossus et al., [@CIT0015]; Luo et al., [@CIT0049]; Pirie et al., [@CIT0059]; Reynolds et al., [@CIT0062]; Wartenberg et al., [@CIT0082]; Xue et al., [@CIT0087]) that found no association of ETS exposure with breast cancer risk, and which together contributed over 60% of the total weight (inverse variance) of the meta-analysis.

We also investigated the effect of adjustment in specific studies, by comparing most- and least-adjusted RR estimates for the principal exposure index, with the estimated ratio indicating no significant systematic difference. However this was based on pairs of estimates from only eight studies.

Overall, the evidence does not suggest any very important role of uncontrolled confounding, and none of the reviews refer to this as a major issue.

Publication bias {#s4I}
----------------

We investigated publication bias formally by a standard test (Egger et al., [@CIT0016]). The results showed some evidence of such bias, consistent with smaller studies finding no association of ETS with breast cancer being less likely to publish their findings. The effect that this would have on the overall association is difficult to assess reliably. Among other things, one should realize that there exist some large prospective studies (e.g. Cancer Prevention Study I) which have reported results relating ETS to other diseases (e.g. Garfinkel, [@CIT0021]) but not for breast cancer risk.

Risk by menopausal status {#s4J}
-------------------------

Of the 23 studies allowing comparison of risks associated with ETS exposure in premenopausal and postmenopausal women, 16 were case-control studies, five were prospective studies and two were case-control studies nested in prospective studies. In the case-control studies menopausal status was as at time of interview, following the diagnosis of the cases, whilst in the prospective studies it was generally at the time of the baseline interview, before follow-up for cancer. In one of the nested studies, Alberg et al. ([@CIT0001]), appears to relate menopausal status to the time of diagnosis of breast cancer. The abstract by Woo et al. ([@CIT0086]) does not make the position clear for the other nested study. Given the length of follow-up was 10 years or more in three prospective studies (Hanaoka et al., [@CIT0023]; Rosenberg et al., [@CIT0068]; Wada et al., [@CIT0079]), some of the women would have reached the menopause between interview and breast cancer diagnosis, so the results from the two types of study are not completely comparable. This problem is less so for Pirie et al. ([@CIT0059]), where follow-up was only for 3.5 years. For the other prospective study we preferred to use the results reported by age at diagnosis (\<50, ≥50 years) published by Reynolds et al. ([@CIT0063]), rather than other results (Reynolds et al., [@CIT0064],[@CIT0062]) based on menopausal status at baseline.

Many of the women who were postmenopausal at the time of cancer onset would have been exposed premenopausally to ETS. Given the latent period of cancer, it seems difficult to explain why, if there indeed is a true effect premenopausally, there would not be some corresponding effect postmenopausally. It remains unclear why (see [Table 10](#t0010){ref-type="table"}) some studies, but not others, should report an increased risk of breast cancer in premenopausal but not postmenopausal women, and how, if there is indeed a true effect, this relates to time of exposure and time of onset. Any proposed relationship needs to fit in with the observed lack of association of breast cancer with ETS exposure in childhood.

Discussing the evidence, the US Surgeon General ([@CIT0078]) noted in 2014 that recent studies have reduced the estimated strength of the relationship of ETS exposure to breast cancer risk in premenopausal women, but "nonetheless, the difference in risk between premenopausal and postmenopausal women remains". They remarked that "it is difficult to ascertain" why the association with passive smoking in premenopausal women should be greater than that for active smoking. They also pointed out that the results from cohort studies do not show an association with passive smoking, and that results "do not support the hypothesis" that passive exposure has "greater carcinogenic effects during periods when breast tissues are less differentiated and more susceptible", noting that "results for exposure to passive smoking during childhood were generally null, regardless of study design".

Commenting on the results of their meta-analyses by menopausal status, Pirie et al. ([@CIT0059]) noted that "The fact that active smoking has little effect on either pre- or post-menopausal women ...... makes it implausible that pre-menopausal women would be especially sensitive to passive exposure", and that, while the finding of an apparent protective effect of passive smoking in premenopausal women in the Million Women study "does not provide good evidence of a real protective effect, it does provide prospective evidence against the view that passive smoking increases the risk of breast cancer in pre-menopausal women and, perhaps more importantly, it illustrates the statistical unreliability of such subgroup analyses". Presumably, this conclusion was reached because of the marginally significant nature of the RR of 0.54 (95% CI 0.30--0.99) and the number of subgroup analyses considered.

Conclusions {#s5}
===========

Given the weak association of active smoking with breast cancer, and the considerably lower exposure to smoke constituents provided by ETS exposure, and given the general problems in detecting small effects in epidemiological studies, it is clearly extremely difficult to reliably determine any true effect of ETS exposure on risk of breast cancer. While the overall evidence suggests an association with some indices of ETS exposure, particularly in premenopausal women, the fact that this association is mainly only seen in case-control studies suggests that recall bias is likely to have been an important contributor to the association. In prospective studies, there is no evidence of an increased risk associated with our principal index "spouse ever smoked or nearest equivalent", regardless of whether detailed questions were asked on ETS exposure. Nor was there any significant association, in prospective studies, with other indices, including spousal, at home, workplace or childhood ETS exposure, or in postmenopausal women. A weak, but significant, association with overall ETS exposure was seen.

Overall, we consider that the available evidence that ETS exposure can cause breast cancer, though to some extent suggestive, is clearly not definitive. In particular, the evidence of an association seen in case-control studies is subject to criticism regarding possible recall bias. Additional evidence is required, particularly from large prospective studies with data on ETS exposure collected at regular intervals, and validated by objective markers (such as cotinine) and by informants other than the subject.

Post script {#s6}
===========

At a late stage, one of the reviewers cited a recent abstract White et al. ([@CIT0085]) which described the results of a prospective study reporting an increased RR of 1.18 (95% CI 1.02--1.38) in nonsmoking women exposed to ETS throughout their childhood, relative to those without any childhood ETS. Though we have not attempted to update our original searches (conducted up to June 2015) to include this and any other very recent studies, we do note that adding in this result to the meta-analyses of childhood exposure in [Table 8](#t0008){ref-type="table"} would have had very little effect, increasing the random-effects RR for all studies from 1.00 (0.95--1.06) to 1.01 (0.96--1.06), and that for prospective studies from 0.98 (0.92--1.04) to 0.99 (0.93--1.05).
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